{"gene":"SPI1","run_date":"2026-06-10T07:46:40","timeline":{"discoveries":[{"year":1996,"finding":"Targeted disruption of the PU.1 DNA-binding domain in mice results in absence of mature macrophages, neutrophils, B cells, and T cells, while erythrocytes and megakaryocytes are preserved, establishing PU.1 as absolutely required for normal differentiation of B cells and macrophages.","method":"Gene knockout mouse (targeted disruption of PU.1 DNA-binding domain), histological and flow cytometric analysis","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO with defined cellular phenotypes, independently replicated by two labs (see PMID:9618756)","pmids":["8896458"],"is_preprint":false},{"year":1988,"finding":"Spi-1/PU.1 was identified as a putative oncogene by retroviral insertional mutagenesis: SFFV proviral integration at the Spi-1 locus was found in 95% of virally induced murine erythroleukemia tumors, with concomitant induction of a 4.0 kb mRNA.","method":"Southern blot integration site analysis, Northern blot expression analysis in primary tumors","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct genomic/expression analysis across large tumor panel, founding identification of locus","pmids":["2827041"],"is_preprint":false},{"year":1998,"finding":"PU.1-null myeloid progenitors fail to respond to M-CSF due to absence of c-fms (M-CSF receptor) gene transcription; retroviral transduction of c-fms restores M-CSF-dependent proliferation but does not induce macrophage differentiation, demonstrating that PU.1 controls myelopoiesis by regulating both cytokine receptor expression and differentiation.","method":"PU.1 knockout mouse-derived progenitors, retroviral transduction of c-fms, cytokine responsiveness assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic rescue experiment with defined molecular readout, loss-of-function plus gain-of-function","pmids":["9687512"],"is_preprint":false},{"year":1998,"finding":"PU.1-null neutrophils fail to terminally differentiate: they lack secondary granule components and are defective in chemokine responses, superoxide production, and bacterial killing; the absence of gp91(phox) mRNA explains the superoxide defect.","method":"PU.1 knockout mouse, flow cytometry, functional assays (superoxide, phagocytosis), RT-PCR","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO with multiple orthogonal functional readouts","pmids":["9716585"],"is_preprint":false},{"year":2002,"finding":"Crystal structure of the PU.1/IRF-4/DNA ternary complex reveals that DNA adopts an unusual S-shape, juxtaposing PU.1 and IRF-4 for selective electrostatic and hydrophobic interactions across the minor groove, providing structural basis for cooperative versus anticooperative interactions between Ets and IRF factors.","method":"X-ray crystallography of ternary complex (PU.1 ETS domain + IRF-4 DBD + composite DNA element)","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with mechanistic interpretation of protein-protein and protein-DNA interactions","pmids":["12453417"],"is_preprint":false},{"year":1999,"finding":"c-Jun acts as a JNK-independent coactivator of PU.1: c-Jun associates via its basic domain with the ETS domain of PU.1 (without binding DNA directly) and enhances PU.1 transactivation of the M-CSF receptor promoter; this interaction is blocked by c-Fos and is stimulated by Ras through upregulation of c-Jun expression.","method":"Co-immunoprecipitation, reporter gene assays, dominant-negative c-Jun constructs, overexpression in cell lines","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal domain mapping and functional assay in single lab","pmids":["9988737"],"is_preprint":false},{"year":2002,"finding":"PU.1 directly regulates transcription of the IL-7Rα gene in lymphoid progenitors; retroviral transduction of IL-7Rα into PU.1-null progenitors restores IL-7-dependent proliferation and, at low frequency, generates pro-B cells.","method":"PU.1 knockout progenitors, promoter analysis, chromatin crosslinking, retroviral transduction rescue","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct promoter binding plus genetic rescue with defined cellular outcome","pmids":["11869689"],"is_preprint":false},{"year":2003,"finding":"PU.1 binds GATA-1 on DNA and recruits pRB (via an acidic N-terminal domain that interacts with pRB's C pocket) to GATA-1 target genes, repressing GATA-1 transcriptional activity and blocking erythroid differentiation; pRB co-localizes with PU.1 and GATA-1 at repressed target genes.","method":"Co-immunoprecipitation, domain-deletion mutagenesis, chromatin immunoprecipitation, reporter assays, differentiation assays in MEL cells","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (Co-IP, ChIP, reporter, mutagenesis) in single study","pmids":["14559995"],"is_preprint":false},{"year":2004,"finding":"PU.1 activation drives dendritic cell fate over macrophage fate by directly binding MafB protein and inhibiting its transcriptional activity and its ability to induce macrophage differentiation; high PU.1 also suppresses MafB expression.","method":"Retroviral overexpression in myeloid progenitors and monocyte clones, protein-protein interaction assays, reporter assays","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct protein interaction plus functional rescue, single lab","pmids":["15598817"],"is_preprint":false},{"year":2005,"finding":"Down-regulation of PU.1 expression in the common myeloid progenitor (CMP) is the first molecularly identified event associated with restriction of differentiation potential to the erythroid/megakaryocyte lineage.","method":"PU.1-GFP reporter knock-in mice, FACS sorting, colony-forming assays, in vivo lineage reconstitution","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — knock-in reporter combined with in vivo reconstitution and functional assays","pmids":["15657291"],"is_preprint":false},{"year":2007,"finding":"MITF and PU.1 form complexes at osteoclast target gene promoters (cathepsin K, acid phosphatase 5) in response to CSF-1 alone; addition of RANKL further recruits p38 MAPK-phosphorylated MITF and SWI/SNF complexes to these promoters; NFATc1 is subsequently recruited during terminal differentiation.","method":"Chromatin immunoprecipitation, co-immunoprecipitation, genetic analysis in Mitf and Pu.1 mouse models, bone marrow-derived precursor differentiation assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP, Co-IP, and in vivo mouse genetics in single study","pmids":["17403683"],"is_preprint":false},{"year":2008,"finding":"Combination of PU.1 and C/EBPα (or C/EBPβ) transdifferentiates NIH 3T3 fibroblasts and skin fibroblasts into macrophage-like cells that phagocytose particles/bacteria, respond to CSF-1, and express myeloid surface markers; PU.1 is the primary inducer of myeloid conversion.","method":"Retroviral transduction of transcription factors into fibroblasts, flow cytometry, phagocytosis assays, gene expression analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct reprogramming with multiple orthogonal functional readouts, multiple cell types tested","pmids":["18424555"],"is_preprint":false},{"year":2009,"finding":"GATA-1 and GATA-2 bind two conserved regions of the PU.1/Sfpi1 gene locus and repress its expression; GATA-1 replaces GATA-2 at the locus during erythromegakaryocytic differentiation, extinguishing PU.1 expression; GATA-2 knockdown in the absence of GATA-1 increases PU.1 expression 3-fold and reprograms cells to macrophages.","method":"ChIP, shRNA knockdown, conditional restoration of GATA-1 in Gata1-null erythromegakaryocytic progenitors, gene expression analysis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP plus genetic perturbation with defined molecular and cellular outcomes","pmids":["19491391"],"is_preprint":false},{"year":2011,"finding":"PU.1 directly controls expression of at least four microRNAs (miR-146a, miR-342, miR-338, miR-155) by occupying binding sites in regulatory chromatin regions near their genomic loci; ectopic miR-146a expression directs HSC differentiation into peritoneal macrophages; disruption of Dicer or antagonization of miR-146a inhibits macrophage formation in zebrafish.","method":"ChIP-seq, miRNA expression profiling, retroviral overexpression in mouse HSCs + transplantation, morpholino knockdown in zebrafish","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP-seq, in vivo transplantation, and zebrafish model with multiple orthogonal methods","pmids":["21730352"],"is_preprint":false},{"year":2013,"finding":"PU.1 controls myeloid differentiation via positive feedback with the cell cycle: developing macrophages increase PU.1 levels by lengthening their cell cycles, causing stable PU.1 accumulation; exogenous PU.1 induces endogenous PU.1 accumulation by lengthening cell cycle, constituting a cell cycle-coupled positive autoregulatory circuit.","method":"Quantitative live-cell imaging of fluorescent PU.1 reporter, exogenous PU.1 expression in progenitors, mathematical modeling","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — live imaging with quantitative single-cell resolution plus mathematical modeling, multiple orthogonal approaches","pmids":["23868921"],"is_preprint":false},{"year":1998,"finding":"The PU.1 PEST domain and IRF-4 residues 1–19 are unstructured in isolation; cooperation between PU.1 and IRF-4 DNA-binding domains at the lambdaB element is spacing-dependent and independent of PEST domain phosphorylation, demonstrating that protein-protein interactions through the DNA-binding domains contribute to cooperative DNA binding.","method":"Fluorescence polarization DNA-binding assays, NMR spectroscopy of 15N-labeled proteins, domain-deletion mutagenesis","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro biochemical reconstitution plus NMR structural analysis, single lab","pmids":["9642085"],"is_preprint":false},{"year":1998,"finding":"Spi-1/PU.1 interacts in vivo with TLS (FUS), an RNA-binding protein; TLS reduces PU.1's DNA-binding and transactivation abilities; Spi-1 and TLS mutually antagonize each other's effects on alternative splicing of E1A pre-mRNA.","method":"Co-immunoprecipitation in vivo, reporter transactivation assays, in vitro/in vivo splicing assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP and functional assays, single lab, multiple readouts","pmids":["9478924"],"is_preprint":false},{"year":2006,"finding":"Spi-1/PU.1 affects alternative splice site selection in a promoter binding-dependent manner: Spi-1 must bind and transactivate a given promoter to favor use of the proximal 5' alternative splice site, indicating coupling of Spi-1's transcriptional and splicing regulatory activities.","method":"Minigene splicing reporter system, Spi-1 domain mutants, transfection in proerythroblastic cells","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional dissection with defined mutants and coupled transcription/splicing reporter, single lab","pmids":["16698794"],"is_preprint":false},{"year":2005,"finding":"PU.1 is acetylated by p300 on lysines 170, 171, 206, and 208; p300 physically interacts with PU.1 residues 7–30; mutation of K170/K171 does not affect DNA binding but lowers transcriptional activation with p300, demonstrating acetylation regulates PU.1 transactivation.","method":"In vitro acetylation assay, co-immunoprecipitation, site-directed mutagenesis, reporter assays, chromatin immunoprecipitation","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro acetylation assay with mutagenesis, Co-IP, ChIP, reporter assays in single study","pmids":["16210620"],"is_preprint":false},{"year":2014,"finding":"The IRF8-PU.1 complex promotes BCL6 and PAX5 expression and represses AID and BLIMP-1, thereby controlling B-cell class-switch recombination and plasma cell differentiation; PU.1-IRF8 functions reciprocally to IRF4.","method":"Conditional knockout mice (B-cell specific deletion), gene expression analysis, functional B-cell differentiation assays","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with defined molecular targets and functional outcomes","pmids":["25288399"],"is_preprint":false},{"year":2015,"finding":"Heterozygous deletion of a PU.1 upstream regulatory enhancer (35% reduction in PU.1 expression) combined with DNA mismatch repair deficiency is sufficient to induce myeloid-biased preleukemic stem cells and their transformation to AML; AML progression involves inhibition of the PU.1-cooperating transcription factor Irf8.","method":"Enhancer deletion mouse model (hypomorphic PU.1), compound genetic crosses with MMR-deficient mice, transplantation assays, gene expression profiling","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — defined genetic perturbation with mechanistic pathway identification and transplantation validation","pmids":["26343801"],"is_preprint":false},{"year":2017,"finding":"Small-molecule heterocyclic diamidine inhibitors allosterically interfere with PU.1-chromatin binding by interacting with the DNA minor groove flanking PU.1-binding motifs, disrupting PU.1 interaction with target gene promoters and downregulating canonical PU.1 transcriptional targets.","method":"Small-molecule inhibitor development, ChIP, reporter assays, shRNA, xenotransplantation mouse models","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — mechanistic drug characterization with ChIP, reporter assays, and in vivo models","pmids":["29083320"],"is_preprint":false},{"year":2016,"finding":"The isosteric selenophene analog DB1976 (unlike DB270) does not bind PU.1 protein directly and strongly inhibits the PU.1/DNA complex in vitro and fully antagonizes PU.1-dependent transactivation in vivo; DB270 binds PU.1 protein independently of DNA, which abrogates its inhibitory activity.","method":"Fluorescence polarization assays, in vitro DNA-binding competition assays, cell-based reporter assays","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with mechanistic dissection of drug/DNA/protein interactions","pmids":["27079976"],"is_preprint":false},{"year":2019,"finding":"PU.1 is an essential regulator of the pro-fibrotic gene expression program in fibroblasts; transcriptional and post-transcriptional mechanisms controlling PU.1 expression are perturbed in fibrotic diseases, upregulating PU.1 and inducing fibrosis-associated gene sets; pharmacological and genetic inactivation of PU.1 reprograms fibrotic fibroblasts into resting fibroblasts and causes regression of fibrosis in multiple organs.","method":"Conditional genetic inactivation, small-molecule PU.1 inhibitors, gene expression profiling, fibrosis models in multiple organs","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO plus pharmacological inhibition with functional rescue across multiple organ fibrosis models","pmids":["30700907"],"is_preprint":false},{"year":2018,"finding":"TNF directly and rapidly upregulates PU.1 protein in HSCs in vitro and in vivo; niche-derived TNF is the principal PU.1-inducing signal in HSCs and is both sufficient and required to relay inflammatory signals to HSCs.","method":"Live-cell imaging, in vivo cytokine administration, genetic ablation of TNF signaling in mice, quantitative single-cell protein measurement","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo and in vitro experiments with genetic and cytokine perturbations","pmids":["30301719"],"is_preprint":false},{"year":2019,"finding":"PU.1 restrains neutrophil innate immune responses by broadly inhibiting enhancer accessibility via recruitment of histone deacetylase 1 (HDAC1); this epigenetic modification prevents AP-1 transcription factor JUNB from accessing chromatin and activating its targets, constituting a PU.1-installed inhibitor program.","method":"Conditional Spi1 deletion in neutrophils, comprehensive epigenomic profiling (ATAC-seq, ChIP-seq), co-immunoprecipitation, fungal infection model","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with genome-wide epigenomic profiling and protein interaction data","pmids":["30911105"],"is_preprint":false},{"year":2020,"finding":"PU.1, in contrast to classical pioneer factors, cannot access nucleosomal target sites in vitro; ectopic PU.1 induction leads to extensive chromatin remodeling and redistribution of partner TFs in vivo; de novo chromatin access and partner TF redistribution require PU.1's N-terminal acidic activation domain and ability to recruit SWI/SNF remodeling complexes.","method":"In vitro nucleosome-binding assays, genome-wide ChIP-seq in multiple cell types with native/ectopic PU.1, ATAC-seq, domain-deletion analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution combined with genome-wide profiling and domain mutagenesis","pmids":["31964861"],"is_preprint":false},{"year":2021,"finding":"PU.1 is required to repress cell cycle and protein synthesis genes in HSCs during IL-1 stimulation; PU.1-deficient HSCs show aberrant protein synthesis and cell cycle activity with IL-1 exposure and undergo expansion; PU.1 directly binds repressed target genes in this context.","method":"Conditional PU.1 knockout in HSCs, IL-1 stimulation, ChIP-seq, gene expression profiling, phenotypic analysis","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with direct ChIP-seq evidence and multiple functional readouts","pmids":["33857288"],"is_preprint":false},{"year":2021,"finding":"Disease-causing heterozygous SPI1 mutations in agammaglobulinemic patients encode destabilized PU.1 proteins unable to nuclear localize or bind target DNA; in PU.1-haploinsufficient pro-B cells, euchromatin is less accessible to non-pioneer TFs critical for B cell development, defining PU.1 as a hematopoietic euchromatin gatekeeper.","method":"Patient-derived SPI1 mutations introduced into human HSPCs, in vitro B-cell and myeloid differentiation assays, ATAC-seq, subcellular localization studies","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — human disease mutations functionally characterized with ATAC-seq and differentiation assays","pmids":["33951726"],"is_preprint":false},{"year":2022,"finding":"SPI1/PU.1 represses genes in the erythroid lineage by binding active enhancers; HDAC1 cooperatively mediates SPI1-induced repression by deacetylating SPI1-bound enhancers, impacting promoter acetylation, chromatin accessibility, and RNA Pol II occupancy; PRC2 reinforces repression by depositing H3K27me3 at promoters; PRC2 and HDAC1 act synergistically.","method":"ChIP-seq, ATAC-seq, RNA-seq, co-immunoprecipitation, pharmacological inhibition of HDAC and PRC2 in murine erythroleukemia cells","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide profiling combined with mechanistic pharmacological dissection and multiple epigenomic readouts","pmids":["35871293"],"is_preprint":false},{"year":2018,"finding":"IRF8 and PU.1 are both required for microglial activation; they directly target each other's gene transcription in a positive feedback loop; they cooperatively bind composite IRF-ETS motifs on microglial activation-related genes, and synergistic binding of IRF8 and PU.1 to composite-motif DNA was verified biochemically.","method":"Post-developmental conditional deletion in microglia, 3D fluorescence imaging, ChIP, in vitro binding assays with composite DNA motifs, gene expression analysis","journal":"Protein & cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with direct ChIP and biochemical DNA-binding validation","pmids":["30484118"],"is_preprint":false},{"year":2019,"finding":"During RANKL-induced osteoclastogenesis, PU.1 switches its transcriptional partner from IRF8 (in precursor macrophages) to NFATc1 (in osteoclasts), altering its genomic binding regions; this partner switching is associated with changes in histone modification and cell-type-specific gene expression.","method":"ChIP-seq, FAIRE-seq, genome-wide chromatin profiling in BMMs and OCs, gene expression analysis","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide ChIP-seq with defined partner switching across differentiation stages","pmids":["30721543"],"is_preprint":false},{"year":2024,"finding":"Cryo-EM/crystal structures of PU.1 bound to a nucleosome containing the CX3CR1 enhancer reveal that PU.1 binds DNA at the exit linker and shifts 17 bp of DNA into the nucleosome core via interactions with H2A, unwrapping ~20 bp; C/EBPα further unwraps ~25 bp of entry DNA aided by PU.1's repositioning; together they displace linker histone H1 and open condensed chromatin arrays. The AML-linked PU.1 Q218H mutation disrupts PU.1-H2A interactions.","method":"Cryo-EM and crystal structure determination of nucleosome complexes, in vitro nucleosome-binding assays, disease mutant analysis","journal":"Nature structural & molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — high-resolution structures with mutagenesis validation and mechanistic functional interpretation","pmids":["38267599"],"is_preprint":false},{"year":2014,"finding":"CTCF and SMARCA5 (ISWI ATPase) are recruited together to the SPI1 gene (including the -14.4 kb enhancer) during normal myeloid differentiation; DNA methylation at the SPI1 locus blocks CTCF binding in AML blasts; upon demethylation, CTCF and SMARCA5 are re-recruited to the SPI1 enhancer.","method":"ChIP assays, AZA-mediated demethylation experiments, co-immunoprecipitation, CTCF knockdown/overexpression","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP with multiple proteins, demethylation experiments, single lab","pmids":["24498324"],"is_preprint":false},{"year":2001,"finding":"Histone deacetylase inhibition with trichostatin A down-regulates PU.1 expression at both mRNA and protein levels, causing loss of PU.1 target gene expression (CD11b, c-fms, TLR4, scavenger receptor); ChIP shows increased histone H4 (but not H3) acetylation across ~650 bp of the PU.1 promoter in TSA-treated cells.","method":"Trichostatin A treatment of multiple cell lines, Northern/Western blot, chromatin immunoprecipitation","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP with functional gene expression readouts across multiple cell lines, single lab","pmids":["11673528"],"is_preprint":false},{"year":2018,"finding":"PU.1 can bind closed genomic sites in developing T cells and rapidly opens them; effective pioneering at closed chromatin requires non-DNA-binding domains of PU.1 beyond site recognition; PU.1 binding affinity and concentration determine occupancy choices with trade-offs between site sequence quality and chromatin accessibility.","method":"Stage-specific gain- and loss-of-function perturbations in pro-T cells, quantitative ChIP-seq, ATAC-seq across PU.1 level dynamics","journal":"Genome research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide occupancy and accessibility profiling combined with gain/loss-of-function perturbations","pmids":["30171019"],"is_preprint":false},{"year":2012,"finding":"HK3 (hexokinase 3) is a direct transcriptional target of PU.1: PU.1 binds the HK3 promoter in vivo; PML-RARA attenuates PU.1 activation of the HK3 promoter; HK3 knockdown impairs neutrophil differentiation and viability of APL cells.","method":"ChIP, reporter assays, siRNA knockdown, gene expression analysis in APL cell lines and primary samples","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and reporter assays with functional knockdown, single lab","pmids":["22498738"],"is_preprint":false},{"year":2015,"finding":"PU.1 directly binds the NFATc1 promoter in osteoclasts and transactivates NFATc1 expression; PU.1 knockdown reduces NFATc1 mRNA, NFATc1 promoter activity, and osteoclast-specific gene expression; enforced PU.1 expression increases NFATc1 and TRAP activity.","method":"ChIP, siRNA knockdown, reporter assays, retroviral overexpression, TRAP activity assays in bone marrow-derived osteoclasts","journal":"Allergology international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP with reporter assay and gain/loss-of-function, single lab","pmids":["26117255"],"is_preprint":false},{"year":2016,"finding":"PU.1 directly activates expression of lncRNA HOTAIRM1 through binding to two PU.1 motifs ~+1100 bp downstream of the HOTAIRM1 transcriptional start site; low HOTAIRM1 expression in APL cells is due to reduced PU.1 expression rather than PML-RARα-mediated direct repression.","method":"ChIP, reporter assays, ectopic PU.1 expression, gene expression analysis","journal":"Journal of hematology & oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and reporter assay with mechanistic dissection, single lab","pmids":["27146823"],"is_preprint":false},{"year":2021,"finding":"PU.1 and IRF8 bind an Ets/IRF composite element (EICE) and an Ets motif at the human NLRP3 distal promoter; knockdown of PU.1 and/or IRF8 reduces NLRP3 expression and markedly diminishes LPS-induced IL-1β release, establishing cooperative PU.1-IRF8 control of monocyte-specific NLRP3 inflammasome activity.","method":"EMSA, ChIP, siRNA knockdown, reporter assays, IL-1β ELISA in THP-1 cells","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA, ChIP, reporter and functional assays, single lab","pmids":["33897697"],"is_preprint":false},{"year":2017,"finding":"Spi-1/PU.1 overexpression triggers cellular senescence in primary hematopoietic (erythroid and myeloid) cells in a DNA-binding-dependent and p38MAPK14-dependent manner (but independent of DNA-damage response); PU.1 overexpression induces senescence in erythroid bone marrow progenitors in vivo before the pre-leukemic phase.","method":"Retroviral overexpression, domain mutants, p38 inhibition, senescence assays (SA-β-gal, Dec1, CDKN1A), Spi-1 transgenic leukemia mouse model, in vivo bone marrow analysis","journal":"Haematologica","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo evidence with domain mutants, single lab","pmids":["28912174"],"is_preprint":false},{"year":2009,"finding":"PU.1 modulates TCR expression in CD4+ T cells by regulating GATA-3's DNA-binding activity and limiting GATA-3's regulation of TCR gene expression; in the absence of PU.1, increased GATA-3 function elevates TCR expression and lowers the T-cell activation threshold.","method":"T-cell-specific conditional PU.1 knockout (lck-Cre), flow cytometry, cytokine secretion assays, GATA-3 activity assays","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with mechanistic GATA-3 interaction analysis, single lab","pmids":["19801513"],"is_preprint":false},{"year":2019,"finding":"Runx1 and PU.1 itself bind the PU.1 upstream regulatory element (URE) in erythroid progenitors; ectopic expression of either Runx1 or PU.1 prevents PU.1 downregulation and blocks terminal erythroid differentiation; Runx1 acting at the URE is required for this block, as ectopic Runx1 fails to block differentiation in BFUe lacking the URE.","method":"Ectopic expression, URE deletion mouse model, ChIP, chromatin accessibility (ATAC-seq), ex vivo differentiation assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic deletion of regulatory element combined with ChIP, ATAC-seq, and rescue experiments","pmids":["31431533"],"is_preprint":false},{"year":2022,"finding":"Tet2 deficiency combined with heterozygous deletion of the PU.1 upstream regulatory element (35% reduction in PU.1) leads to highly penetrant, transplantable AML; leukemic cells show hypermethylation at PU.1-binding sites and fail to activate myeloid enhancers, uncovering a methylation-sensitive PU.1-dependent gene network as a molecular vulnerability in AML.","method":"Compound mouse genetics (Tet2 KO + PU.1 UREΔ/WT), transplantation assays, WGBS, ChIP-seq, ATAC-seq, gene expression profiling","journal":"Blood cancer discovery","confidence":"High","confidence_rationale":"Tier 2 / Strong — defined compound genetics with genome-wide mechanistic evidence and transplantation validation","pmids":["35820129"],"is_preprint":false},{"year":2018,"finding":"EOMES forms a complex with PU.1 and MITF at osteoclast-specific genomic loci as demonstrated by co-immunoprecipitation and sequential ChIP; EOMES knockdown in myeloid precursors leads to osteopetrosis with decreased osteoclast differentiation and function both in vitro and in vivo.","method":"Co-immunoprecipitation, sequential ChIP (re-ChIP), EOMES shRNA knockdown, in vitro differentiation, in vivo bone analysis","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — sequential ChIP demonstrating complex plus in vivo functional validation, single lab","pmids":["30634169"],"is_preprint":false},{"year":2024,"finding":"PU.1 directly binds the IL-9 promoter to activate its transcription in Th9 cells; Th9-derived IL-9 induces PU.1 expression via the IL-9R-JAK1/STAT3 signaling pathway, forming a positive feedback loop; this loop promotes inflammatory macrophage activation and fibroblast-like synoviocyte hyperactivation in rheumatoid arthritis.","method":"ChIP-qPCR, luciferase reporter assay, siRNA knockdown, IL-9 recombinant protein, conditional PU.1 KO mice (CAIA model), collagen-induced arthritis model","journal":"Annals of the rheumatic diseases","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP, reporter assays, and in vivo genetic models, single lab","pmids":["39164066"],"is_preprint":false}],"current_model":"SPI1/PU.1 is an ETS-family transcription factor and pioneer factor that functions as the master regulator of hematopoietic lineage commitment: it directly binds nucleosomal DNA (unwrapping ~20 bp via histone H2A contacts, as revealed by cryo-EM) and recruits SWI/SNF and HDAC1 complexes to remodel chromatin; its concentration determines cell fate (highest levels drive macrophage/dendritic cell differentiation, lower levels permit granulocyte or B-cell development); it transactivates cytokine receptor genes (c-fms, G-CSFR, GM-CSFR, IL-7Rα) to enable lineage-specific cytokine responsiveness; it cooperatively binds composite ETS-IRF elements with IRF4, IRF8, and ICSBP; it is post-translationally acetylated by p300 on K170/171/206/208 to modulate its transactivation; it recruits pRB to GATA-1 target genes to suppress erythroid differentiation; it is regulated by TNF-induced signals in HSCs, by GATA-1/GATA-2 repression of its locus, and by Runx1 acting at its upstream regulatory element; and pharmacological inhibition via minor-groove-binding diamidines that allosterically disrupt PU.1-chromatin contacts has therapeutic activity in AML models."},"narrative":{"mechanistic_narrative":"SPI1/PU.1 is an ETS-family transcription factor that acts as the master regulator of hematopoietic lineage commitment, where its dose dictates cell fate and its loss abolishes development of B cells, macrophages, and functionally competent neutrophils [PMID:8896458, PMID:9716585, PMID:15657291]. PU.1 operates as a chromatin pioneer: cryo-EM and crystallographic structures show it engages nucleosomal DNA at the exit linker, shifting ~17 bp into the core through contacts with histone H2A to unwrap ~20 bp and, together with C/EBPα, displace linker histone H1 to open condensed chromatin [PMID:38267599]. Although PU.1 cannot fully access nucleosomal sites in isolation in vitro, its N-terminal acidic activation domain recruits SWI/SNF remodeling complexes to drive de novo chromatin access and redistribute partner transcription factors in vivo [PMID:31964861, PMID:30171019]. It functions combinatorially through composite ETS-IRF elements with IRF4 and IRF8 — interactions defined structurally and biochemically — programming distinct B-cell, microglial, and inflammasome gene sets [PMID:12453417, PMID:9642085, PMID:25288399, PMID:30484118]. Beyond activation, PU.1 enforces lineage repression: it recruits HDAC1 to deacetylate bound enhancers (reinforced by PRC2-deposited H3K27me3) to silence erythroid and innate-immune programs, and partners with pRB to block GATA-1-driven erythroid differentiation [PMID:14559995, PMID:30911105, PMID:35871293]. PU.1 transactivates cytokine-receptor genes including c-fms and IL-7Rα to license lineage-specific cytokine responsiveness, and it is itself controlled by a regulatory architecture spanning TNF-induced induction in HSCs, GATA-1/GATA-2 repression of its locus, Runx1 action at its upstream regulatory element, and cell-cycle-coupled positive autoregulation [PMID:9687512, PMID:11869689, PMID:19491391, PMID:23868921, PMID:30301719, PMID:31431533]. PU.1 acts as a hematopoietic euchromatin gatekeeper whose haploinsufficiency causes agammaglobulinemia in humans, and hypomorphic PU.1 cooperates with mismatch-repair or Tet2 deficiency to drive AML, a context in which minor-groove-binding diamidines that allosterically disrupt PU.1-chromatin contacts show therapeutic activity [PMID:29083320, PMID:33951726, PMID:35820129]. PU.1 additionally drives pro-fibrotic fibroblast programs, and its pharmacological inactivation reverses fibrosis [PMID:30700907].","teleology":[{"year":1988,"claim":"Established the locus as a candidate oncogene by linking its activation to virally induced leukemia, motivating all subsequent functional study.","evidence":"Retroviral integration site and expression analysis across murine erythroleukemia tumors","pmids":["2827041"],"confidence":"High","gaps":["Did not define the protein's molecular activity","No mechanism linking overexpression to transformation"]},{"year":1996,"claim":"Resolved whether PU.1 is required for hematopoietic development by showing its DNA-binding function is essential for B cell and macrophage differentiation while sparing erythroid/megakaryocytic lineages.","evidence":"Targeted disruption of the PU.1 DNA-binding domain in mice with histology and flow cytometry","pmids":["8896458"],"confidence":"High","gaps":["Direct target genes not identified","Did not separate lineage-specification from terminal-differentiation roles"]},{"year":1998,"claim":"Defined how PU.1 enables lineage-specific cytokine responsiveness by showing it is required for transcription of the M-CSF receptor c-fms, and separated receptor expression from differentiation.","evidence":"PU.1-null progenitors with retroviral c-fms rescue and cytokine assays; parallel functional analysis of null neutrophils","pmids":["9687512","9716585"],"confidence":"High","gaps":["Receptor rescue did not restore differentiation, leaving differentiation targets undefined"]},{"year":1998,"claim":"Provided biochemical/structural basis for combinatorial control by demonstrating spacing-dependent cooperative DNA binding between PU.1 and IRF-4 through their DNA-binding domains.","evidence":"Fluorescence polarization, NMR, and domain-deletion analysis at the lambdaB element; in vivo Co-IP with TLS/FUS as an additional interactor","pmids":["9642085","9478924"],"confidence":"High","gaps":["Atomic structure of the cooperative complex not yet resolved","TLS/FUS interaction was Medium-confidence single-lab"]},{"year":2002,"claim":"Delivered the atomic basis for PU.1/IRF cooperativity, explaining how composite elements select cooperative versus anticooperative pairings, and extended PU.1's reach into lymphoid cytokine signaling via IL-7Rα.","evidence":"X-ray structure of PU.1/IRF-4/DNA ternary complex; promoter analysis and retroviral IL-7Rα rescue in null progenitors","pmids":["12453417","11869689"],"confidence":"High","gaps":["Structure used isolated DNA-binding domains, not full-length factors","Did not address nucleosomal context"]},{"year":2003,"claim":"Showed PU.1 acts as a repressor of competing lineages by binding GATA-1 and recruiting pRB to block erythroid differentiation, establishing antagonistic cross-regulation of fate.","evidence":"Co-IP, domain mutagenesis, ChIP, and differentiation assays in MEL cells","pmids":["14559995"],"confidence":"High","gaps":["Genome-wide scope of PU.1-pRB co-occupancy not defined","In vivo relevance not tested"]},{"year":2005,"claim":"Identified post-translational and dose-based tuning of PU.1 output: p300 acetylation of specific lysines modulates transactivation, and PU.1 down-regulation marks the earliest molecular step restricting CMPs to erythroid/megakaryocytic fate.","evidence":"In vitro acetylation, mutagenesis, ChIP and reporter assays; PU.1-GFP reporter knock-in mice with in vivo reconstitution","pmids":["16210620","15657291"],"confidence":"High","gaps":["Acetyltransferase/deacetylase balance in vivo not mapped","Upstream signals setting PU.1 dose not yet identified"]},{"year":2008,"claim":"Demonstrated PU.1's instructive sufficiency by showing PU.1 (with C/EBP) transdifferentiates fibroblasts into functional macrophage-like cells.","evidence":"Retroviral transcription-factor transduction into fibroblasts with phagocytosis and marker assays","pmids":["18424555"],"confidence":"High","gaps":["Did not resolve the chromatin mechanism enabling conversion","C/EBP dependency not mechanistically dissected"]},{"year":2011,"claim":"Expanded PU.1's regulatory repertoire to non-coding RNA, showing it directly drives myeloid-instructive microRNAs in vivo.","evidence":"ChIP-seq, retroviral HSC overexpression with transplantation, zebrafish morpholino knockdown","pmids":["21730352"],"confidence":"High","gaps":["Relative contribution of miRNA versus protein-coding targets to fate unclear"]},{"year":2013,"claim":"Explained how PU.1 dose is stabilized during commitment by uncovering a cell-cycle-coupled positive autoregulatory circuit.","evidence":"Quantitative live-cell imaging of a PU.1 reporter with mathematical modeling","pmids":["23868921"],"confidence":"High","gaps":["Molecular link between cell-cycle length and PU.1 accumulation not defined"]},{"year":2014,"claim":"Mapped PU.1 locus regulation and B-lineage programming, defining CTCF/SMARCA5 recruitment to the SPI1 enhancer and the reciprocal IRF8 versus IRF4 partnerships controlling B-cell differentiation.","evidence":"Conditional B-cell knockout with expression analysis; ChIP and demethylation experiments at the SPI1 locus","pmids":["25288399","24498324"],"confidence":"High","gaps":["CTCF/SMARCA5 result was Medium-confidence single-lab","Direct DNA contacts of IRF8-PU.1 at B-cell targets not structurally resolved"]},{"year":2015,"claim":"Causally linked PU.1 dose reduction to leukemogenesis, showing hypomorphic PU.1 plus MMR deficiency generates preleukemic stem cells and AML through Irf8 inhibition.","evidence":"PU.1 enhancer-deletion mouse crossed to MMR-deficient mice with transplantation and expression profiling","pmids":["26343801"],"confidence":"High","gaps":["Did not define the full PU.1-dependent network lost during transformation"]},{"year":2017,"claim":"Provided a pharmacological strategy and senescence mechanism: minor-groove diamidines allosterically block PU.1-chromatin binding with AML activity, while PU.1 overexpression triggers DNA-binding-dependent senescence.","evidence":"Small-molecule inhibitors with ChIP and xenotransplant models; overexpression with domain mutants and senescence assays in vivo","pmids":["29083320","28912174"],"confidence":"High","gaps":["Senescence study was Medium-confidence single-lab","Selectivity of diamidines for PU.1 sites genome-wide not fully resolved"]},{"year":2018,"claim":"Resolved the diamidine mechanism and clarified PU.1's upstream control and partner switching: inhibitory diamidines act through DNA minor-groove binding (not protein binding), TNF is the principal PU.1-inducing signal in HSCs, and PU.1 swaps IRF8 for NFATc1 across osteoclast differentiation.","evidence":"FP and DNA-binding competition assays; in vivo TNF perturbation with single-cell imaging; ChIP-seq across BMM-to-osteoclast transition and microglial conditional deletion","pmids":["27079976","30301719","30721543","30484118"],"confidence":"High","gaps":["How TNF signaling is transduced to PU.1 protein stabilization not detailed"]},{"year":2019,"claim":"Established PU.1 as a repressive chromatin organizer beyond hematopoiesis: it recruits HDAC1 to restrain neutrophil enhancers and drives pro-fibrotic fibroblast programs reversible by PU.1 inactivation; Runx1 and PU.1 enforce its own URE-dependent maintenance in erythroid cells.","evidence":"Conditional Spi1 deletion with ATAC-seq/ChIP-seq and Co-IP; conditional/pharmacological PU.1 inactivation across fibrosis models; URE-deletion mouse with ChIP and ATAC-seq","pmids":["30911105","30700907","31431533"],"confidence":"High","gaps":["Mechanism switching PU.1 between activator and repressor functions per locus unresolved"]},{"year":2020,"claim":"Reframed PU.1 pioneering: rather than directly accessing nucleosomes, PU.1 uses its acidic activation domain to recruit SWI/SNF for de novo chromatin opening and partner redistribution.","evidence":"In vitro nucleosome-binding assays plus genome-wide ChIP-seq/ATAC-seq with domain deletions; pro-T-cell perturbations defining affinity/concentration trade-offs","pmids":["31964861","30171019"],"confidence":"High","gaps":["Structural basis of nucleosome engagement not yet shown","Identity of recruited remodeler subunits incompletely defined"]},{"year":2021,"claim":"Showed PU.1 functions as a human euchromatin gatekeeper and an inflammation-restraining repressor: agammaglobulinemia-causing mutations destabilize PU.1 and close euchromatin, and PU.1 represses cell-cycle/protein-synthesis genes during IL-1 stress in HSCs.","evidence":"Patient SPI1 mutations in human HSPCs with ATAC-seq and differentiation; conditional HSC knockout with IL-1 stimulation and ChIP-seq","pmids":["33951726","33857288"],"confidence":"High","gaps":["How haploinsufficiency selectively closes specific euchromatin domains not fully mapped"]},{"year":2022,"claim":"Defined the mechanistic basis of PU.1-mediated repression and methylation-sensitive leukemogenesis: PU.1 recruits HDAC1 and synergizes with PRC2 at erythroid enhancers, while Tet2 loss plus hypomorphic PU.1 drives AML via hypermethylated PU.1 sites and failed myeloid enhancer activation.","evidence":"ChIP-seq/ATAC-seq/RNA-seq with HDAC/PRC2 inhibition in MEL cells; compound Tet2-KO/URE-deletion mouse genetics with WGBS and transplantation","pmids":["35871293","35820129"],"confidence":"High","gaps":["Locus-specific cues directing PU.1 to repressive versus activating complexes unresolved"]},{"year":2024,"claim":"Delivered the structural mechanism of PU.1 pioneering on a native nucleosome, showing H2A-dependent DNA unwrapping cooperative with C/EBPα and H1 displacement, and rationalizing an AML mutation.","evidence":"Cryo-EM/crystal structures of PU.1-nucleosome complexes with in vitro binding assays and Q218H mutant analysis; also IL-9/PU.1 feedback loop in arthritis (Medium)","pmids":["38267599","39164066"],"confidence":"High","gaps":["Structures captured a single enhancer context","In vivo coupling of unwrapping to SWI/SNF recruitment not directly visualized"]},{"year":null,"claim":"It remains unresolved what locus-specific molecular determinants direct PU.1 between activating (SWI/SNF) and repressive (HDAC1/PRC2) chromatin programs, and how PU.1 dose, post-translational modification, and partner availability are integrated to set these choices genome-wide.","evidence":"","pmids":[],"confidence":"High","gaps":["No unified model linking PU.1 concentration to activator-versus-repressor outcome at individual loci","Determinants of cofactor selection (p300 vs HDAC1 vs PRC2) per site unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,2,6,7,19,26,30]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[4,15,32,35,28]},{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[32]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[26,25,29]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[28]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[32,26]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,2,6,26]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[25,26,29,32]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[0,9,11,14]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[3,19,25,30,39]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[1,20,28,43]}],"complexes":["PU.1/IRF composite-element complex (with IRF4/IRF8)","PU.1/MITF osteoclast complex"],"partners":["IRF4","IRF8","GATA1","RB1","MITF","HDAC1","CEBPA","NFATC1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P17947","full_name":"Transcription factor PU.1","aliases":["31 kDa-transforming protein"],"length_aa":270,"mass_kda":31.1,"function":"Pioneer transcription factor, which controls hematopoietic cell fate by decompacting stem cell heterochromatin and allowing other transcription factors to enter otherwise inaccessible genomic sites. Once in open chromatin, can directly control gene expression by binding genetic regulatory elements and can also more broadly influence transcription by recruiting transcription factors, such as interferon regulatory factors (IRFs), to otherwise inaccessible genomic regions (PubMed:23658224, PubMed:33951726). Transcriptionally activates genes important for myeloid and lymphoid lineages, such as CSF1R (By similarity). Transcriptional activation from certain promoters, possibly containing low affinity binding sites, is achieved cooperatively with other transcription factors. FCER1A transactivation is achieved in cooperation with GATA1 (By similarity). May be particularly important for the pro- to pre-B cell transition (PubMed:33951726). Binds (via the ETS domain) onto the purine-rich DNA core sequence 5'-GAGGAA-3', also known as the PU-box (PubMed:33951726). In vitro can bind RNA and interfere with pre-mRNA splicing (By similarity)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P17947/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SPI1","classification":"Not Classified","n_dependent_lines":36,"n_total_lines":1208,"dependency_fraction":0.029801324503311258},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SPI1","total_profiled":1310},"omim":[{"mim_id":"621210","title":"PU.1 (SPI1)-INDUCED REGULATOR OF S100A8 AND S100A9 ALARMIN TRANSCRIPTION 1, NONCODING; PIRAT1","url":"https://www.omim.org/entry/621210"},{"mim_id":"619707","title":"AGAMMAGLOBULINEMIA 10, AUTOSOMAL DOMINANT; AGM10","url":"https://www.omim.org/entry/619707"},{"mim_id":"615772","title":"WAP FOUR-DISULFIDE CORE DOMAIN 21, PSEUDOGENE; WFDC21P","url":"https://www.omim.org/entry/615772"},{"mim_id":"613065","title":"LEUKEMIA, ACUTE LYMPHOBLASTIC; ALL","url":"https://www.omim.org/entry/613065"},{"mim_id":"612568","title":"SPIC TRANSCRIPTION FACTOR; SPIC","url":"https://www.omim.org/entry/612568"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"bone marrow","ntpm":316.4},{"tissue":"lung","ntpm":98.6},{"tissue":"lymphoid tissue","ntpm":167.9}],"url":"https://www.proteinatlas.org/search/SPI1"},"hgnc":{"alias_symbol":["PU.1","SPI-A","OF","SFPI1","SPI-1"],"prev_symbol":[]},"alphafold":{"accession":"P17947","domains":[{"cath_id":"1.10.10.10","chopping":"171-258","consensus_level":"high","plddt":97.1716,"start":171,"end":258}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P17947","model_url":"https://alphafold.ebi.ac.uk/files/AF-P17947-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P17947-F1-predicted_aligned_error_v6.png","plddt_mean":65.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SPI1","jax_strain_url":"https://www.jax.org/strain/search?query=SPI1"},"sequence":{"accession":"P17947","fasta_url":"https://rest.uniprot.org/uniprotkb/P17947.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P17947/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P17947"}},"corpus_meta":[{"pmid":"8896458","id":"PMC_8896458","title":"Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities.","date":"1996","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/8896458","citation_count":906,"is_preprint":false},{"pmid":"2827041","id":"PMC_2827041","title":"Spi-1 is a putative oncogene in virally induced murine erythroleukaemias.","date":"1988","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/2827041","citation_count":452,"is_preprint":false},{"pmid":"18424555","id":"PMC_18424555","title":"PU.1 and C/EBPalpha/beta convert fibroblasts into macrophage-like cells.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18424555","citation_count":294,"is_preprint":false},{"pmid":"31428589","id":"PMC_31428589","title":"Salmonella Pathogenicity Island 1 (SPI-1) and Its Complex Regulatory Network.","date":"2019","source":"Frontiers in cellular and infection microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/31428589","citation_count":259,"is_preprint":false},{"pmid":"9687512","id":"PMC_9687512","title":"PU.1 regulates both cytokine-dependent proliferation and differentiation of granulocyte/macrophage progenitors.","date":"1998","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9687512","citation_count":250,"is_preprint":false},{"pmid":"15657291","id":"PMC_15657291","title":"Dynamic regulation of PU.1 expression in multipotent hematopoietic progenitors.","date":"2005","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15657291","citation_count":249,"is_preprint":false},{"pmid":"23868921","id":"PMC_23868921","title":"Positive feedback between PU.1 and the cell cycle controls myeloid differentiation.","date":"2013","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/23868921","citation_count":232,"is_preprint":false},{"pmid":"11869689","id":"PMC_11869689","title":"PU.1 regulates expression of the interleukin-7 receptor in lymphoid progenitors.","date":"2002","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/11869689","citation_count":229,"is_preprint":false},{"pmid":"8628313","id":"PMC_8628313","title":"Spi-1/PU.1 transgenic mice develop multistep erythroleukemias.","date":"1996","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8628313","citation_count":173,"is_preprint":false},{"pmid":"30700907","id":"PMC_30700907","title":"PU.1 controls fibroblast polarization and tissue fibrosis.","date":"2019","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/30700907","citation_count":164,"is_preprint":false},{"pmid":"9988737","id":"PMC_9988737","title":"c-Jun is a JNK-independent coactivator of the PU.1 transcription factor.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9988737","citation_count":153,"is_preprint":false},{"pmid":"15598817","id":"PMC_15598817","title":"Balance of MafB and PU.1 specifies alternative macrophage or dendritic cell fate.","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15598817","citation_count":151,"is_preprint":false},{"pmid":"18799744","id":"PMC_18799744","title":"HilD-mediated transcriptional cross-talk between SPI-1 and SPI-2.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18799744","citation_count":145,"is_preprint":false},{"pmid":"17403683","id":"PMC_17403683","title":"MITF and PU.1 recruit p38 MAPK and NFATc1 to target genes during osteoclast differentiation.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17403683","citation_count":142,"is_preprint":false},{"pmid":"9474745","id":"PMC_9474745","title":"Role of PU.1 in hematopoiesis.","date":"1998","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/9474745","citation_count":136,"is_preprint":false},{"pmid":"12453417","id":"PMC_12453417","title":"Crystal structure of PU.1/IRF-4/DNA ternary complex.","date":"2002","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/12453417","citation_count":132,"is_preprint":false},{"pmid":"25288399","id":"PMC_25288399","title":"The transcription factors IRF8 and PU.1 negatively regulate plasma cell differentiation.","date":"2014","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25288399","citation_count":122,"is_preprint":false},{"pmid":"9716585","id":"PMC_9716585","title":"Neutrophils deficient in PU.1 do not terminally differentiate or become functionally competent.","date":"1998","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9716585","citation_count":122,"is_preprint":false},{"pmid":"8585944","id":"PMC_8585944","title":"Function of PU.1 (Spi-1), C/EBP, and AML1 in early myelopoiesis: regulation of multiple myeloid CSF receptor promoters.","date":"1996","source":"Current topics in microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8585944","citation_count":119,"is_preprint":false},{"pmid":"9478924","id":"PMC_9478924","title":"The transcription factor Spi-1/PU.1 interacts with the potential splicing factor TLS.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9478924","citation_count":117,"is_preprint":false},{"pmid":"28671687","id":"PMC_28671687","title":"Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia.","date":"2017","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28671687","citation_count":111,"is_preprint":false},{"pmid":"26343801","id":"PMC_26343801","title":"Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia.","date":"2015","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26343801","citation_count":111,"is_preprint":false},{"pmid":"31964861","id":"PMC_31964861","title":"Mechanisms governing the pioneering and redistribution capabilities of the non-classical pioneer PU.1.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31964861","citation_count":105,"is_preprint":false},{"pmid":"29083320","id":"PMC_29083320","title":"Pharmacological inhibition of the transcription factor PU.1 in leukemia.","date":"2017","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/29083320","citation_count":102,"is_preprint":false},{"pmid":"21730352","id":"PMC_21730352","title":"Macrophage development from HSCs requires PU.1-coordinated microRNA expression.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21730352","citation_count":99,"is_preprint":false},{"pmid":"19491391","id":"PMC_19491391","title":"Graded repression of PU.1/Sfpi1 gene transcription by GATA factors regulates hematopoietic cell fate.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19491391","citation_count":90,"is_preprint":false},{"pmid":"27671860","id":"PMC_27671860","title":"MicroRNA-155 influences B-cell function through PU.1 in rheumatoid arthritis.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/27671860","citation_count":85,"is_preprint":false},{"pmid":"14559995","id":"PMC_14559995","title":"PU.1 and pRB interact and cooperate to repress GATA-1 and block erythroid differentiation.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/14559995","citation_count":85,"is_preprint":false},{"pmid":"17374502","id":"PMC_17374502","title":"PU.1: a crucial and versatile player in hematopoiesis and leukemia.","date":"2007","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/17374502","citation_count":83,"is_preprint":false},{"pmid":"23749759","id":"PMC_23749759","title":"Knockdown of PU.1 AS lncRNA inhibits adipogenesis through enhancing PU.1 mRNA translation.","date":"2013","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23749759","citation_count":77,"is_preprint":false},{"pmid":"25749719","id":"PMC_25749719","title":"The RUNX1-PU.1 axis in the control of hematopoiesis.","date":"2015","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/25749719","citation_count":76,"is_preprint":false},{"pmid":"33857288","id":"PMC_33857288","title":"PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress.","date":"2021","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33857288","citation_count":75,"is_preprint":false},{"pmid":"20969585","id":"PMC_20969585","title":"Surprising new roles for PU.1 in the adaptive immune response.","date":"2010","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/20969585","citation_count":72,"is_preprint":false},{"pmid":"33125129","id":"PMC_33125129","title":"Transcription factor PU.1 and immune cell differentiation (Review).","date":"2020","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33125129","citation_count":69,"is_preprint":false},{"pmid":"25574134","id":"PMC_25574134","title":"A Comprehensive Profile of ChIP-Seq-Based PU.1/Spi1 Target Genes in Microglia.","date":"2014","source":"Gene regulation and systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/25574134","citation_count":67,"is_preprint":false},{"pmid":"30484118","id":"PMC_30484118","title":"Transcriptional mechanism of IRF8 and PU.1 governs microglial activation in neurodegenerative condition.","date":"2018","source":"Protein & cell","url":"https://pubmed.ncbi.nlm.nih.gov/30484118","citation_count":67,"is_preprint":false},{"pmid":"16158816","id":"PMC_16158816","title":"Role of transcription factors C/EBPalpha and PU.1 in normal hematopoiesis and leukemia.","date":"2005","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/16158816","citation_count":65,"is_preprint":false},{"pmid":"12972030","id":"PMC_12972030","title":"The importance of PU.1 concentration in hematopoietic lineage commitment and maturation.","date":"2003","source":"Blood cells, molecules & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/12972030","citation_count":65,"is_preprint":false},{"pmid":"30171019","id":"PMC_30171019","title":"Pioneering, chromatin remodeling, and epigenetic constraint in early T-cell gene regulation by SPI1 (PU.1).","date":"2018","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/30171019","citation_count":64,"is_preprint":false},{"pmid":"17267285","id":"PMC_17267285","title":"Is PU.1 a dosage-sensitive regulator of haemopoietic lineage commitment and leukaemogenesis?","date":"2007","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17267285","citation_count":61,"is_preprint":false},{"pmid":"11673528","id":"PMC_11673528","title":"Loss of PU.1 expression following inhibition of histone deacetylases.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11673528","citation_count":61,"is_preprint":false},{"pmid":"19801513","id":"PMC_19801513","title":"PU.1 regulates TCR expression by modulating GATA-3 activity.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19801513","citation_count":59,"is_preprint":false},{"pmid":"19382896","id":"PMC_19382896","title":"PU.1 and partners: regulation of haematopoietic stem cell fate in normal and malignant haematopoiesis.","date":"2009","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19382896","citation_count":59,"is_preprint":false},{"pmid":"11325034","id":"PMC_11325034","title":"PU.1/Interferon Regulatory Factor interactions: mechanisms of transcriptional regulation.","date":"2000","source":"Cell biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/11325034","citation_count":59,"is_preprint":false},{"pmid":"30301719","id":"PMC_30301719","title":"Inflammatory signals directly instruct PU.1 in HSCs via TNF.","date":"2018","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/30301719","citation_count":59,"is_preprint":false},{"pmid":"10713349","id":"PMC_10713349","title":"PU.1 expression in microglia.","date":"2000","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/10713349","citation_count":52,"is_preprint":false},{"pmid":"26932576","id":"PMC_26932576","title":"PU.1 cooperates with IRF4 and IRF8 to suppress pre-B-cell leukemia.","date":"2016","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/26932576","citation_count":52,"is_preprint":false},{"pmid":"33951726","id":"PMC_33951726","title":"Constrained chromatin accessibility in PU.1-mutated agammaglobulinemia patients.","date":"2021","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33951726","citation_count":51,"is_preprint":false},{"pmid":"22498738","id":"PMC_22498738","title":"PU.1 is linking the glycolytic enzyme HK3 in neutrophil differentiation and survival of APL cells.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22498738","citation_count":49,"is_preprint":false},{"pmid":"27146823","id":"PMC_27146823","title":"PU.1 controls the expression of long noncoding RNA HOTAIRM1 during granulocytic differentiation.","date":"2016","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27146823","citation_count":48,"is_preprint":false},{"pmid":"25205721","id":"PMC_25205721","title":"Epigenetic control of hematopoiesis: the PU.1 chromatin connection.","date":"2014","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25205721","citation_count":43,"is_preprint":false},{"pmid":"30911105","id":"PMC_30911105","title":"Safeguard function of PU.1 shapes the inflammatory epigenome of neutrophils.","date":"2019","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30911105","citation_count":43,"is_preprint":false},{"pmid":"32135178","id":"PMC_32135178","title":"Inhibition of PU.1 ameliorates metabolic dysfunction and non-alcoholic steatohepatitis.","date":"2020","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/32135178","citation_count":40,"is_preprint":false},{"pmid":"24445817","id":"PMC_24445817","title":"PU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/HOX pathway.","date":"2013","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/24445817","citation_count":40,"is_preprint":false},{"pmid":"8389910","id":"PMC_8389910","title":"The PU.1/Spi-1 proto-oncogene is a transcriptional regulator of a lentivirus promoter.","date":"1993","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/8389910","citation_count":39,"is_preprint":false},{"pmid":"33863903","id":"PMC_33863903","title":"Genetic perturbation of PU.1 binding and chromatin looping at neutrophil enhancers associates with autoimmune disease.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33863903","citation_count":38,"is_preprint":false},{"pmid":"11980719","id":"PMC_11980719","title":"Spi-B can functionally replace PU.1 in myeloid but not lymphoid development.","date":"2002","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/11980719","citation_count":37,"is_preprint":false},{"pmid":"9618756","id":"PMC_9618756","title":"PU.1 and hematopoiesis: lessons learned from gene targeting experiments.","date":"1998","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9618756","citation_count":36,"is_preprint":false},{"pmid":"30291285","id":"PMC_30291285","title":"Contribution of SPI-1 bistability to Salmonella enterica cooperative virulence: insights from single cell analysis.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30291285","citation_count":36,"is_preprint":false},{"pmid":"28232093","id":"PMC_28232093","title":"Epigenomic PU.1-VDR crosstalk modulates vitamin D signaling.","date":"2017","source":"Biochimica et biophysica acta. Gene regulatory mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/28232093","citation_count":34,"is_preprint":false},{"pmid":"26361334","id":"PMC_26361334","title":"PU.1 Suppresses Th2 Cytokine Expression via Silencing of GATA3 Transcription in Dendritic Cells.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26361334","citation_count":34,"is_preprint":false},{"pmid":"21094529","id":"PMC_21094529","title":"CLEC5A (MDL-1) is a novel PU.1 transcriptional target during myeloid differentiation.","date":"2010","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21094529","citation_count":34,"is_preprint":false},{"pmid":"9642085","id":"PMC_9642085","title":"Cooperative interaction between the DNA-binding domains of PU.1 and IRF4.","date":"1998","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9642085","citation_count":34,"is_preprint":false},{"pmid":"30721543","id":"PMC_30721543","title":"Cooperation of PU.1 With IRF8 and NFATc1 Defines Chromatin Landscapes During RANKL-Induced Osteoclastogenesis.","date":"2019","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/30721543","citation_count":32,"is_preprint":false},{"pmid":"27079976","id":"PMC_27079976","title":"Pharmacologic efficacy of PU.1 inhibition by heterocyclic dications: a mechanistic analysis.","date":"2016","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/27079976","citation_count":32,"is_preprint":false},{"pmid":"16210620","id":"PMC_16210620","title":"Protein acetylation regulates both PU.1 transactivation and Ig kappa 3' enhancer activity.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16210620","citation_count":31,"is_preprint":false},{"pmid":"19167354","id":"PMC_19167354","title":"Transcriptomic profiling identifies a PU.1 regulatory network in macrophages.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19167354","citation_count":31,"is_preprint":false},{"pmid":"36118415","id":"PMC_36118415","title":"LINC01094/SPI1/CCL7 Axis Promotes Macrophage Accumulation in Lung Adenocarcinoma and Tumor Cell Dissemination.","date":"2022","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/36118415","citation_count":30,"is_preprint":false},{"pmid":"24498324","id":"PMC_24498324","title":"Epigenetic control of SPI1 gene by CTCF and ISWI ATPase SMARCA5.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24498324","citation_count":30,"is_preprint":false},{"pmid":"32379601","id":"PMC_32379601","title":"Abnormal expression of colony stimulating factor 1 receptor (CSF1R) and transcription factor PU.1 (SPI1) in the spleen from patients with major psychiatric disorders: A role of brain-spleen axis.","date":"2020","source":"Journal of affective disorders","url":"https://pubmed.ncbi.nlm.nih.gov/32379601","citation_count":30,"is_preprint":false},{"pmid":"35608913","id":"PMC_35608913","title":"Isolevuglandins disrupt PU.1-mediated C1q expression and promote autoimmunity and hypertension in systemic lupus erythematosus.","date":"2022","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/35608913","citation_count":29,"is_preprint":false},{"pmid":"34714913","id":"PMC_34714913","title":"BCL11A promotes myeloid leukemogenesis by repressing PU.1 target genes.","date":"2022","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/34714913","citation_count":28,"is_preprint":false},{"pmid":"15013752","id":"PMC_15013752","title":"Functional analysis of PU.1 domains in monocyte-specific gene regulation.","date":"2004","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/15013752","citation_count":28,"is_preprint":false},{"pmid":"21878674","id":"PMC_21878674","title":"Sox4 cooperates with PU.1 haploinsufficiency in murine myeloid leukemia.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21878674","citation_count":27,"is_preprint":false},{"pmid":"11114304","id":"PMC_11114304","title":"PU.1 is a lineage-specific regulator of tyrosine phosphatase CD45.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11114304","citation_count":27,"is_preprint":false},{"pmid":"24575107","id":"PMC_24575107","title":"The SPI-1-like Type III secretion system: more roles than you think.","date":"2014","source":"Frontiers in plant science","url":"https://pubmed.ncbi.nlm.nih.gov/24575107","citation_count":26,"is_preprint":false},{"pmid":"29467892","id":"PMC_29467892","title":"Transcription factor PU.1 is involved in the progression of glioma.","date":"2018","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/29467892","citation_count":26,"is_preprint":false},{"pmid":"16698794","id":"PMC_16698794","title":"Spi-1/PU.1 oncoprotein affects splicing decisions in a promoter binding-dependent manner.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16698794","citation_count":25,"is_preprint":false},{"pmid":"22231443","id":"PMC_22231443","title":"Ikaros represses and activates PU.1 cell-type-specifically through the multifunctional Sfpi1 URE and a myeloid specific enhancer.","date":"2012","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/22231443","citation_count":24,"is_preprint":false},{"pmid":"35871293","id":"PMC_35871293","title":"HDAC1 and PRC2 mediate combinatorial control in SPI1/PU.1-dependent gene repression in murine erythroleukaemia.","date":"2022","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/35871293","citation_count":24,"is_preprint":false},{"pmid":"19825991","id":"PMC_19825991","title":"PU.1 activation relieves GATA-1-mediated repression of Cebpa and Cbfb during leukemia differentiation.","date":"2009","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/19825991","citation_count":24,"is_preprint":false},{"pmid":"28912174","id":"PMC_28912174","title":"Senescence is a Spi1-induced anti-proliferative mechanism in primary hematopoietic cells.","date":"2017","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/28912174","citation_count":24,"is_preprint":false},{"pmid":"10085160","id":"PMC_10085160","title":"PU.1 and USF are required for macrophage-specific mannose receptor promoter activity.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10085160","citation_count":23,"is_preprint":false},{"pmid":"30634169","id":"PMC_30634169","title":"Eomes partners with PU.1 and MITF to Regulate Transcription Factors Critical for osteoclast differentiation.","date":"2018","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/30634169","citation_count":23,"is_preprint":false},{"pmid":"26117255","id":"PMC_26117255","title":"Involvement of PU.1 in NFATc1 promoter function in osteoclast development.","date":"2015","source":"Allergology international : official journal of the Japanese Society of Allergology","url":"https://pubmed.ncbi.nlm.nih.gov/26117255","citation_count":23,"is_preprint":false},{"pmid":"33897697","id":"PMC_33897697","title":"PU.1 and IRF8 Modulate Activation of NLRP3 Inflammasome via Regulating Its Expression in Human Macrophages.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33897697","citation_count":22,"is_preprint":false},{"pmid":"19131555","id":"PMC_19131555","title":"Essential role of spi-1-like (spi-1l) in zebrafish myeloid cell differentiation.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19131555","citation_count":22,"is_preprint":false},{"pmid":"37607234","id":"PMC_37607234","title":"Human FAM111A inhibits vaccinia virus replication by degrading viral protein I3 and is antagonized by poxvirus host range factor SPI-1.","date":"2023","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/37607234","citation_count":21,"is_preprint":false},{"pmid":"31471020","id":"PMC_31471020","title":"LncRNA PU.1 AS regulates arsenic-induced lipid metabolism through EZH2/Sirt6/SREBP-1c pathway.","date":"2019","source":"Journal of environmental sciences (China)","url":"https://pubmed.ncbi.nlm.nih.gov/31471020","citation_count":21,"is_preprint":false},{"pmid":"39164066","id":"PMC_39164066","title":"Positive feedback loop PU.1-IL9 in Th9 promotes rheumatoid arthritis development.","date":"2024","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/39164066","citation_count":20,"is_preprint":false},{"pmid":"38267599","id":"PMC_38267599","title":"Structural mechanism of synergistic targeting of the CX3CR1 nucleosome by PU.1 and C/EBPα.","date":"2024","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/38267599","citation_count":20,"is_preprint":false},{"pmid":"33786950","id":"PMC_33786950","title":"Upregulation of the pathogenic transcription factor SPI1/PU.1 in tuberous sclerosis complex and focal cortical dysplasia by oxidative stress.","date":"2021","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/33786950","citation_count":20,"is_preprint":false},{"pmid":"35820129","id":"PMC_35820129","title":"PU.1-Dependent Enhancer Inhibition Separates Tet2-Deficient Hematopoiesis from Malignant Transformation.","date":"2022","source":"Blood cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/35820129","citation_count":19,"is_preprint":false},{"pmid":"25840997","id":"PMC_25840997","title":"Nrf2 regulates PU.1 expression and activity in the alveolar macrophage.","date":"2015","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/25840997","citation_count":19,"is_preprint":false},{"pmid":"22790984","id":"PMC_22790984","title":"Spi-1/PU.1 activates transcription through clustered DNA occupancy in erythroleukemia.","date":"2012","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/22790984","citation_count":19,"is_preprint":false},{"pmid":"37325511","id":"PMC_37325511","title":"Salmonella Enteritidis activates inflammatory storm via SPI-1 and SPI-2 to promote intracellular proliferation and bacterial virulence.","date":"2023","source":"Frontiers in cellular and infection microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/37325511","citation_count":18,"is_preprint":false},{"pmid":"39455096","id":"PMC_39455096","title":"SPI1+CD68+ macrophages as a biomarker for gastric cancer metastasis: a rationale for combined antiangiogenic and immunotherapy strategies.","date":"2024","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/39455096","citation_count":17,"is_preprint":false},{"pmid":"38960279","id":"PMC_38960279","title":"The role of SPI1/VSIG4/THBS1 on glioblastoma progression through modulation of the PI3K/AKT pathway.","date":"2024","source":"Journal of advanced research","url":"https://pubmed.ncbi.nlm.nih.gov/38960279","citation_count":17,"is_preprint":false},{"pmid":"18371060","id":"PMC_18371060","title":"CD34, RAB20, PU.1 and GFI1 mRNA expression in myelodysplastic syndrome.","date":"2008","source":"International journal of laboratory hematology","url":"https://pubmed.ncbi.nlm.nih.gov/18371060","citation_count":17,"is_preprint":false},{"pmid":"31431533","id":"PMC_31431533","title":"Runx1 promotes murine erythroid progenitor proliferation and inhibits differentiation by preventing Pu.1 downregulation.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/31431533","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47719,"output_tokens":10657,"usd":0.151506,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":21319,"output_tokens":6251,"usd":0.131435,"stage2_stop_reason":"end_turn"},"total_usd":0.282941,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"Targeted disruption of the PU.1 DNA-binding domain in mice results in absence of mature macrophages, neutrophils, B cells, and T cells, while erythrocytes and megakaryocytes are preserved, establishing PU.1 as absolutely required for normal differentiation of B cells and macrophages.\",\n      \"method\": \"Gene knockout mouse (targeted disruption of PU.1 DNA-binding domain), histological and flow cytometric analysis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO with defined cellular phenotypes, independently replicated by two labs (see PMID:9618756)\",\n      \"pmids\": [\"8896458\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"Spi-1/PU.1 was identified as a putative oncogene by retroviral insertional mutagenesis: SFFV proviral integration at the Spi-1 locus was found in 95% of virally induced murine erythroleukemia tumors, with concomitant induction of a 4.0 kb mRNA.\",\n      \"method\": \"Southern blot integration site analysis, Northern blot expression analysis in primary tumors\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct genomic/expression analysis across large tumor panel, founding identification of locus\",\n      \"pmids\": [\"2827041\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"PU.1-null myeloid progenitors fail to respond to M-CSF due to absence of c-fms (M-CSF receptor) gene transcription; retroviral transduction of c-fms restores M-CSF-dependent proliferation but does not induce macrophage differentiation, demonstrating that PU.1 controls myelopoiesis by regulating both cytokine receptor expression and differentiation.\",\n      \"method\": \"PU.1 knockout mouse-derived progenitors, retroviral transduction of c-fms, cytokine responsiveness assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic rescue experiment with defined molecular readout, loss-of-function plus gain-of-function\",\n      \"pmids\": [\"9687512\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"PU.1-null neutrophils fail to terminally differentiate: they lack secondary granule components and are defective in chemokine responses, superoxide production, and bacterial killing; the absence of gp91(phox) mRNA explains the superoxide defect.\",\n      \"method\": \"PU.1 knockout mouse, flow cytometry, functional assays (superoxide, phagocytosis), RT-PCR\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO with multiple orthogonal functional readouts\",\n      \"pmids\": [\"9716585\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Crystal structure of the PU.1/IRF-4/DNA ternary complex reveals that DNA adopts an unusual S-shape, juxtaposing PU.1 and IRF-4 for selective electrostatic and hydrophobic interactions across the minor groove, providing structural basis for cooperative versus anticooperative interactions between Ets and IRF factors.\",\n      \"method\": \"X-ray crystallography of ternary complex (PU.1 ETS domain + IRF-4 DBD + composite DNA element)\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with mechanistic interpretation of protein-protein and protein-DNA interactions\",\n      \"pmids\": [\"12453417\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"c-Jun acts as a JNK-independent coactivator of PU.1: c-Jun associates via its basic domain with the ETS domain of PU.1 (without binding DNA directly) and enhances PU.1 transactivation of the M-CSF receptor promoter; this interaction is blocked by c-Fos and is stimulated by Ras through upregulation of c-Jun expression.\",\n      \"method\": \"Co-immunoprecipitation, reporter gene assays, dominant-negative c-Jun constructs, overexpression in cell lines\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal domain mapping and functional assay in single lab\",\n      \"pmids\": [\"9988737\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"PU.1 directly regulates transcription of the IL-7Rα gene in lymphoid progenitors; retroviral transduction of IL-7Rα into PU.1-null progenitors restores IL-7-dependent proliferation and, at low frequency, generates pro-B cells.\",\n      \"method\": \"PU.1 knockout progenitors, promoter analysis, chromatin crosslinking, retroviral transduction rescue\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct promoter binding plus genetic rescue with defined cellular outcome\",\n      \"pmids\": [\"11869689\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PU.1 binds GATA-1 on DNA and recruits pRB (via an acidic N-terminal domain that interacts with pRB's C pocket) to GATA-1 target genes, repressing GATA-1 transcriptional activity and blocking erythroid differentiation; pRB co-localizes with PU.1 and GATA-1 at repressed target genes.\",\n      \"method\": \"Co-immunoprecipitation, domain-deletion mutagenesis, chromatin immunoprecipitation, reporter assays, differentiation assays in MEL cells\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (Co-IP, ChIP, reporter, mutagenesis) in single study\",\n      \"pmids\": [\"14559995\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"PU.1 activation drives dendritic cell fate over macrophage fate by directly binding MafB protein and inhibiting its transcriptional activity and its ability to induce macrophage differentiation; high PU.1 also suppresses MafB expression.\",\n      \"method\": \"Retroviral overexpression in myeloid progenitors and monocyte clones, protein-protein interaction assays, reporter assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct protein interaction plus functional rescue, single lab\",\n      \"pmids\": [\"15598817\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Down-regulation of PU.1 expression in the common myeloid progenitor (CMP) is the first molecularly identified event associated with restriction of differentiation potential to the erythroid/megakaryocyte lineage.\",\n      \"method\": \"PU.1-GFP reporter knock-in mice, FACS sorting, colony-forming assays, in vivo lineage reconstitution\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knock-in reporter combined with in vivo reconstitution and functional assays\",\n      \"pmids\": [\"15657291\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"MITF and PU.1 form complexes at osteoclast target gene promoters (cathepsin K, acid phosphatase 5) in response to CSF-1 alone; addition of RANKL further recruits p38 MAPK-phosphorylated MITF and SWI/SNF complexes to these promoters; NFATc1 is subsequently recruited during terminal differentiation.\",\n      \"method\": \"Chromatin immunoprecipitation, co-immunoprecipitation, genetic analysis in Mitf and Pu.1 mouse models, bone marrow-derived precursor differentiation assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP, Co-IP, and in vivo mouse genetics in single study\",\n      \"pmids\": [\"17403683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Combination of PU.1 and C/EBPα (or C/EBPβ) transdifferentiates NIH 3T3 fibroblasts and skin fibroblasts into macrophage-like cells that phagocytose particles/bacteria, respond to CSF-1, and express myeloid surface markers; PU.1 is the primary inducer of myeloid conversion.\",\n      \"method\": \"Retroviral transduction of transcription factors into fibroblasts, flow cytometry, phagocytosis assays, gene expression analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct reprogramming with multiple orthogonal functional readouts, multiple cell types tested\",\n      \"pmids\": [\"18424555\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"GATA-1 and GATA-2 bind two conserved regions of the PU.1/Sfpi1 gene locus and repress its expression; GATA-1 replaces GATA-2 at the locus during erythromegakaryocytic differentiation, extinguishing PU.1 expression; GATA-2 knockdown in the absence of GATA-1 increases PU.1 expression 3-fold and reprograms cells to macrophages.\",\n      \"method\": \"ChIP, shRNA knockdown, conditional restoration of GATA-1 in Gata1-null erythromegakaryocytic progenitors, gene expression analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP plus genetic perturbation with defined molecular and cellular outcomes\",\n      \"pmids\": [\"19491391\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PU.1 directly controls expression of at least four microRNAs (miR-146a, miR-342, miR-338, miR-155) by occupying binding sites in regulatory chromatin regions near their genomic loci; ectopic miR-146a expression directs HSC differentiation into peritoneal macrophages; disruption of Dicer or antagonization of miR-146a inhibits macrophage formation in zebrafish.\",\n      \"method\": \"ChIP-seq, miRNA expression profiling, retroviral overexpression in mouse HSCs + transplantation, morpholino knockdown in zebrafish\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP-seq, in vivo transplantation, and zebrafish model with multiple orthogonal methods\",\n      \"pmids\": [\"21730352\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"PU.1 controls myeloid differentiation via positive feedback with the cell cycle: developing macrophages increase PU.1 levels by lengthening their cell cycles, causing stable PU.1 accumulation; exogenous PU.1 induces endogenous PU.1 accumulation by lengthening cell cycle, constituting a cell cycle-coupled positive autoregulatory circuit.\",\n      \"method\": \"Quantitative live-cell imaging of fluorescent PU.1 reporter, exogenous PU.1 expression in progenitors, mathematical modeling\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — live imaging with quantitative single-cell resolution plus mathematical modeling, multiple orthogonal approaches\",\n      \"pmids\": [\"23868921\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The PU.1 PEST domain and IRF-4 residues 1–19 are unstructured in isolation; cooperation between PU.1 and IRF-4 DNA-binding domains at the lambdaB element is spacing-dependent and independent of PEST domain phosphorylation, demonstrating that protein-protein interactions through the DNA-binding domains contribute to cooperative DNA binding.\",\n      \"method\": \"Fluorescence polarization DNA-binding assays, NMR spectroscopy of 15N-labeled proteins, domain-deletion mutagenesis\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro biochemical reconstitution plus NMR structural analysis, single lab\",\n      \"pmids\": [\"9642085\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Spi-1/PU.1 interacts in vivo with TLS (FUS), an RNA-binding protein; TLS reduces PU.1's DNA-binding and transactivation abilities; Spi-1 and TLS mutually antagonize each other's effects on alternative splicing of E1A pre-mRNA.\",\n      \"method\": \"Co-immunoprecipitation in vivo, reporter transactivation assays, in vitro/in vivo splicing assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP and functional assays, single lab, multiple readouts\",\n      \"pmids\": [\"9478924\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Spi-1/PU.1 affects alternative splice site selection in a promoter binding-dependent manner: Spi-1 must bind and transactivate a given promoter to favor use of the proximal 5' alternative splice site, indicating coupling of Spi-1's transcriptional and splicing regulatory activities.\",\n      \"method\": \"Minigene splicing reporter system, Spi-1 domain mutants, transfection in proerythroblastic cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional dissection with defined mutants and coupled transcription/splicing reporter, single lab\",\n      \"pmids\": [\"16698794\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"PU.1 is acetylated by p300 on lysines 170, 171, 206, and 208; p300 physically interacts with PU.1 residues 7–30; mutation of K170/K171 does not affect DNA binding but lowers transcriptional activation with p300, demonstrating acetylation regulates PU.1 transactivation.\",\n      \"method\": \"In vitro acetylation assay, co-immunoprecipitation, site-directed mutagenesis, reporter assays, chromatin immunoprecipitation\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro acetylation assay with mutagenesis, Co-IP, ChIP, reporter assays in single study\",\n      \"pmids\": [\"16210620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The IRF8-PU.1 complex promotes BCL6 and PAX5 expression and represses AID and BLIMP-1, thereby controlling B-cell class-switch recombination and plasma cell differentiation; PU.1-IRF8 functions reciprocally to IRF4.\",\n      \"method\": \"Conditional knockout mice (B-cell specific deletion), gene expression analysis, functional B-cell differentiation assays\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with defined molecular targets and functional outcomes\",\n      \"pmids\": [\"25288399\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Heterozygous deletion of a PU.1 upstream regulatory enhancer (35% reduction in PU.1 expression) combined with DNA mismatch repair deficiency is sufficient to induce myeloid-biased preleukemic stem cells and their transformation to AML; AML progression involves inhibition of the PU.1-cooperating transcription factor Irf8.\",\n      \"method\": \"Enhancer deletion mouse model (hypomorphic PU.1), compound genetic crosses with MMR-deficient mice, transplantation assays, gene expression profiling\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — defined genetic perturbation with mechanistic pathway identification and transplantation validation\",\n      \"pmids\": [\"26343801\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Small-molecule heterocyclic diamidine inhibitors allosterically interfere with PU.1-chromatin binding by interacting with the DNA minor groove flanking PU.1-binding motifs, disrupting PU.1 interaction with target gene promoters and downregulating canonical PU.1 transcriptional targets.\",\n      \"method\": \"Small-molecule inhibitor development, ChIP, reporter assays, shRNA, xenotransplantation mouse models\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanistic drug characterization with ChIP, reporter assays, and in vivo models\",\n      \"pmids\": [\"29083320\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"The isosteric selenophene analog DB1976 (unlike DB270) does not bind PU.1 protein directly and strongly inhibits the PU.1/DNA complex in vitro and fully antagonizes PU.1-dependent transactivation in vivo; DB270 binds PU.1 protein independently of DNA, which abrogates its inhibitory activity.\",\n      \"method\": \"Fluorescence polarization assays, in vitro DNA-binding competition assays, cell-based reporter assays\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with mechanistic dissection of drug/DNA/protein interactions\",\n      \"pmids\": [\"27079976\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PU.1 is an essential regulator of the pro-fibrotic gene expression program in fibroblasts; transcriptional and post-transcriptional mechanisms controlling PU.1 expression are perturbed in fibrotic diseases, upregulating PU.1 and inducing fibrosis-associated gene sets; pharmacological and genetic inactivation of PU.1 reprograms fibrotic fibroblasts into resting fibroblasts and causes regression of fibrosis in multiple organs.\",\n      \"method\": \"Conditional genetic inactivation, small-molecule PU.1 inhibitors, gene expression profiling, fibrosis models in multiple organs\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO plus pharmacological inhibition with functional rescue across multiple organ fibrosis models\",\n      \"pmids\": [\"30700907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TNF directly and rapidly upregulates PU.1 protein in HSCs in vitro and in vivo; niche-derived TNF is the principal PU.1-inducing signal in HSCs and is both sufficient and required to relay inflammatory signals to HSCs.\",\n      \"method\": \"Live-cell imaging, in vivo cytokine administration, genetic ablation of TNF signaling in mice, quantitative single-cell protein measurement\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo and in vitro experiments with genetic and cytokine perturbations\",\n      \"pmids\": [\"30301719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PU.1 restrains neutrophil innate immune responses by broadly inhibiting enhancer accessibility via recruitment of histone deacetylase 1 (HDAC1); this epigenetic modification prevents AP-1 transcription factor JUNB from accessing chromatin and activating its targets, constituting a PU.1-installed inhibitor program.\",\n      \"method\": \"Conditional Spi1 deletion in neutrophils, comprehensive epigenomic profiling (ATAC-seq, ChIP-seq), co-immunoprecipitation, fungal infection model\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with genome-wide epigenomic profiling and protein interaction data\",\n      \"pmids\": [\"30911105\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PU.1, in contrast to classical pioneer factors, cannot access nucleosomal target sites in vitro; ectopic PU.1 induction leads to extensive chromatin remodeling and redistribution of partner TFs in vivo; de novo chromatin access and partner TF redistribution require PU.1's N-terminal acidic activation domain and ability to recruit SWI/SNF remodeling complexes.\",\n      \"method\": \"In vitro nucleosome-binding assays, genome-wide ChIP-seq in multiple cell types with native/ectopic PU.1, ATAC-seq, domain-deletion analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution combined with genome-wide profiling and domain mutagenesis\",\n      \"pmids\": [\"31964861\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PU.1 is required to repress cell cycle and protein synthesis genes in HSCs during IL-1 stimulation; PU.1-deficient HSCs show aberrant protein synthesis and cell cycle activity with IL-1 exposure and undergo expansion; PU.1 directly binds repressed target genes in this context.\",\n      \"method\": \"Conditional PU.1 knockout in HSCs, IL-1 stimulation, ChIP-seq, gene expression profiling, phenotypic analysis\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with direct ChIP-seq evidence and multiple functional readouts\",\n      \"pmids\": [\"33857288\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Disease-causing heterozygous SPI1 mutations in agammaglobulinemic patients encode destabilized PU.1 proteins unable to nuclear localize or bind target DNA; in PU.1-haploinsufficient pro-B cells, euchromatin is less accessible to non-pioneer TFs critical for B cell development, defining PU.1 as a hematopoietic euchromatin gatekeeper.\",\n      \"method\": \"Patient-derived SPI1 mutations introduced into human HSPCs, in vitro B-cell and myeloid differentiation assays, ATAC-seq, subcellular localization studies\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — human disease mutations functionally characterized with ATAC-seq and differentiation assays\",\n      \"pmids\": [\"33951726\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SPI1/PU.1 represses genes in the erythroid lineage by binding active enhancers; HDAC1 cooperatively mediates SPI1-induced repression by deacetylating SPI1-bound enhancers, impacting promoter acetylation, chromatin accessibility, and RNA Pol II occupancy; PRC2 reinforces repression by depositing H3K27me3 at promoters; PRC2 and HDAC1 act synergistically.\",\n      \"method\": \"ChIP-seq, ATAC-seq, RNA-seq, co-immunoprecipitation, pharmacological inhibition of HDAC and PRC2 in murine erythroleukemia cells\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide profiling combined with mechanistic pharmacological dissection and multiple epigenomic readouts\",\n      \"pmids\": [\"35871293\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"IRF8 and PU.1 are both required for microglial activation; they directly target each other's gene transcription in a positive feedback loop; they cooperatively bind composite IRF-ETS motifs on microglial activation-related genes, and synergistic binding of IRF8 and PU.1 to composite-motif DNA was verified biochemically.\",\n      \"method\": \"Post-developmental conditional deletion in microglia, 3D fluorescence imaging, ChIP, in vitro binding assays with composite DNA motifs, gene expression analysis\",\n      \"journal\": \"Protein & cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with direct ChIP and biochemical DNA-binding validation\",\n      \"pmids\": [\"30484118\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"During RANKL-induced osteoclastogenesis, PU.1 switches its transcriptional partner from IRF8 (in precursor macrophages) to NFATc1 (in osteoclasts), altering its genomic binding regions; this partner switching is associated with changes in histone modification and cell-type-specific gene expression.\",\n      \"method\": \"ChIP-seq, FAIRE-seq, genome-wide chromatin profiling in BMMs and OCs, gene expression analysis\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide ChIP-seq with defined partner switching across differentiation stages\",\n      \"pmids\": [\"30721543\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Cryo-EM/crystal structures of PU.1 bound to a nucleosome containing the CX3CR1 enhancer reveal that PU.1 binds DNA at the exit linker and shifts 17 bp of DNA into the nucleosome core via interactions with H2A, unwrapping ~20 bp; C/EBPα further unwraps ~25 bp of entry DNA aided by PU.1's repositioning; together they displace linker histone H1 and open condensed chromatin arrays. The AML-linked PU.1 Q218H mutation disrupts PU.1-H2A interactions.\",\n      \"method\": \"Cryo-EM and crystal structure determination of nucleosome complexes, in vitro nucleosome-binding assays, disease mutant analysis\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — high-resolution structures with mutagenesis validation and mechanistic functional interpretation\",\n      \"pmids\": [\"38267599\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CTCF and SMARCA5 (ISWI ATPase) are recruited together to the SPI1 gene (including the -14.4 kb enhancer) during normal myeloid differentiation; DNA methylation at the SPI1 locus blocks CTCF binding in AML blasts; upon demethylation, CTCF and SMARCA5 are re-recruited to the SPI1 enhancer.\",\n      \"method\": \"ChIP assays, AZA-mediated demethylation experiments, co-immunoprecipitation, CTCF knockdown/overexpression\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP with multiple proteins, demethylation experiments, single lab\",\n      \"pmids\": [\"24498324\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Histone deacetylase inhibition with trichostatin A down-regulates PU.1 expression at both mRNA and protein levels, causing loss of PU.1 target gene expression (CD11b, c-fms, TLR4, scavenger receptor); ChIP shows increased histone H4 (but not H3) acetylation across ~650 bp of the PU.1 promoter in TSA-treated cells.\",\n      \"method\": \"Trichostatin A treatment of multiple cell lines, Northern/Western blot, chromatin immunoprecipitation\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP with functional gene expression readouts across multiple cell lines, single lab\",\n      \"pmids\": [\"11673528\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PU.1 can bind closed genomic sites in developing T cells and rapidly opens them; effective pioneering at closed chromatin requires non-DNA-binding domains of PU.1 beyond site recognition; PU.1 binding affinity and concentration determine occupancy choices with trade-offs between site sequence quality and chromatin accessibility.\",\n      \"method\": \"Stage-specific gain- and loss-of-function perturbations in pro-T cells, quantitative ChIP-seq, ATAC-seq across PU.1 level dynamics\",\n      \"journal\": \"Genome research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide occupancy and accessibility profiling combined with gain/loss-of-function perturbations\",\n      \"pmids\": [\"30171019\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"HK3 (hexokinase 3) is a direct transcriptional target of PU.1: PU.1 binds the HK3 promoter in vivo; PML-RARA attenuates PU.1 activation of the HK3 promoter; HK3 knockdown impairs neutrophil differentiation and viability of APL cells.\",\n      \"method\": \"ChIP, reporter assays, siRNA knockdown, gene expression analysis in APL cell lines and primary samples\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and reporter assays with functional knockdown, single lab\",\n      \"pmids\": [\"22498738\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PU.1 directly binds the NFATc1 promoter in osteoclasts and transactivates NFATc1 expression; PU.1 knockdown reduces NFATc1 mRNA, NFATc1 promoter activity, and osteoclast-specific gene expression; enforced PU.1 expression increases NFATc1 and TRAP activity.\",\n      \"method\": \"ChIP, siRNA knockdown, reporter assays, retroviral overexpression, TRAP activity assays in bone marrow-derived osteoclasts\",\n      \"journal\": \"Allergology international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP with reporter assay and gain/loss-of-function, single lab\",\n      \"pmids\": [\"26117255\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PU.1 directly activates expression of lncRNA HOTAIRM1 through binding to two PU.1 motifs ~+1100 bp downstream of the HOTAIRM1 transcriptional start site; low HOTAIRM1 expression in APL cells is due to reduced PU.1 expression rather than PML-RARα-mediated direct repression.\",\n      \"method\": \"ChIP, reporter assays, ectopic PU.1 expression, gene expression analysis\",\n      \"journal\": \"Journal of hematology & oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and reporter assay with mechanistic dissection, single lab\",\n      \"pmids\": [\"27146823\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PU.1 and IRF8 bind an Ets/IRF composite element (EICE) and an Ets motif at the human NLRP3 distal promoter; knockdown of PU.1 and/or IRF8 reduces NLRP3 expression and markedly diminishes LPS-induced IL-1β release, establishing cooperative PU.1-IRF8 control of monocyte-specific NLRP3 inflammasome activity.\",\n      \"method\": \"EMSA, ChIP, siRNA knockdown, reporter assays, IL-1β ELISA in THP-1 cells\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA, ChIP, reporter and functional assays, single lab\",\n      \"pmids\": [\"33897697\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Spi-1/PU.1 overexpression triggers cellular senescence in primary hematopoietic (erythroid and myeloid) cells in a DNA-binding-dependent and p38MAPK14-dependent manner (but independent of DNA-damage response); PU.1 overexpression induces senescence in erythroid bone marrow progenitors in vivo before the pre-leukemic phase.\",\n      \"method\": \"Retroviral overexpression, domain mutants, p38 inhibition, senescence assays (SA-β-gal, Dec1, CDKN1A), Spi-1 transgenic leukemia mouse model, in vivo bone marrow analysis\",\n      \"journal\": \"Haematologica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo evidence with domain mutants, single lab\",\n      \"pmids\": [\"28912174\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PU.1 modulates TCR expression in CD4+ T cells by regulating GATA-3's DNA-binding activity and limiting GATA-3's regulation of TCR gene expression; in the absence of PU.1, increased GATA-3 function elevates TCR expression and lowers the T-cell activation threshold.\",\n      \"method\": \"T-cell-specific conditional PU.1 knockout (lck-Cre), flow cytometry, cytokine secretion assays, GATA-3 activity assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with mechanistic GATA-3 interaction analysis, single lab\",\n      \"pmids\": [\"19801513\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Runx1 and PU.1 itself bind the PU.1 upstream regulatory element (URE) in erythroid progenitors; ectopic expression of either Runx1 or PU.1 prevents PU.1 downregulation and blocks terminal erythroid differentiation; Runx1 acting at the URE is required for this block, as ectopic Runx1 fails to block differentiation in BFUe lacking the URE.\",\n      \"method\": \"Ectopic expression, URE deletion mouse model, ChIP, chromatin accessibility (ATAC-seq), ex vivo differentiation assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic deletion of regulatory element combined with ChIP, ATAC-seq, and rescue experiments\",\n      \"pmids\": [\"31431533\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Tet2 deficiency combined with heterozygous deletion of the PU.1 upstream regulatory element (35% reduction in PU.1) leads to highly penetrant, transplantable AML; leukemic cells show hypermethylation at PU.1-binding sites and fail to activate myeloid enhancers, uncovering a methylation-sensitive PU.1-dependent gene network as a molecular vulnerability in AML.\",\n      \"method\": \"Compound mouse genetics (Tet2 KO + PU.1 UREΔ/WT), transplantation assays, WGBS, ChIP-seq, ATAC-seq, gene expression profiling\",\n      \"journal\": \"Blood cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — defined compound genetics with genome-wide mechanistic evidence and transplantation validation\",\n      \"pmids\": [\"35820129\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"EOMES forms a complex with PU.1 and MITF at osteoclast-specific genomic loci as demonstrated by co-immunoprecipitation and sequential ChIP; EOMES knockdown in myeloid precursors leads to osteopetrosis with decreased osteoclast differentiation and function both in vitro and in vivo.\",\n      \"method\": \"Co-immunoprecipitation, sequential ChIP (re-ChIP), EOMES shRNA knockdown, in vitro differentiation, in vivo bone analysis\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — sequential ChIP demonstrating complex plus in vivo functional validation, single lab\",\n      \"pmids\": [\"30634169\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PU.1 directly binds the IL-9 promoter to activate its transcription in Th9 cells; Th9-derived IL-9 induces PU.1 expression via the IL-9R-JAK1/STAT3 signaling pathway, forming a positive feedback loop; this loop promotes inflammatory macrophage activation and fibroblast-like synoviocyte hyperactivation in rheumatoid arthritis.\",\n      \"method\": \"ChIP-qPCR, luciferase reporter assay, siRNA knockdown, IL-9 recombinant protein, conditional PU.1 KO mice (CAIA model), collagen-induced arthritis model\",\n      \"journal\": \"Annals of the rheumatic diseases\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, reporter assays, and in vivo genetic models, single lab\",\n      \"pmids\": [\"39164066\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SPI1/PU.1 is an ETS-family transcription factor and pioneer factor that functions as the master regulator of hematopoietic lineage commitment: it directly binds nucleosomal DNA (unwrapping ~20 bp via histone H2A contacts, as revealed by cryo-EM) and recruits SWI/SNF and HDAC1 complexes to remodel chromatin; its concentration determines cell fate (highest levels drive macrophage/dendritic cell differentiation, lower levels permit granulocyte or B-cell development); it transactivates cytokine receptor genes (c-fms, G-CSFR, GM-CSFR, IL-7Rα) to enable lineage-specific cytokine responsiveness; it cooperatively binds composite ETS-IRF elements with IRF4, IRF8, and ICSBP; it is post-translationally acetylated by p300 on K170/171/206/208 to modulate its transactivation; it recruits pRB to GATA-1 target genes to suppress erythroid differentiation; it is regulated by TNF-induced signals in HSCs, by GATA-1/GATA-2 repression of its locus, and by Runx1 acting at its upstream regulatory element; and pharmacological inhibition via minor-groove-binding diamidines that allosterically disrupt PU.1-chromatin contacts has therapeutic activity in AML models.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SPI1/PU.1 is an ETS-family transcription factor that acts as the master regulator of hematopoietic lineage commitment, where its dose dictates cell fate and its loss abolishes development of B cells, macrophages, and functionally competent neutrophils [#0, #3, #9]. PU.1 operates as a chromatin pioneer: cryo-EM and crystallographic structures show it engages nucleosomal DNA at the exit linker, shifting ~17 bp into the core through contacts with histone H2A to unwrap ~20 bp and, together with C/EBPα, displace linker histone H1 to open condensed chromatin [#32]. Although PU.1 cannot fully access nucleosomal sites in isolation in vitro, its N-terminal acidic activation domain recruits SWI/SNF remodeling complexes to drive de novo chromatin access and redistribute partner transcription factors in vivo [#26, #35]. It functions combinatorially through composite ETS-IRF elements with IRF4 and IRF8 — interactions defined structurally and biochemically — programming distinct B-cell, microglial, and inflammasome gene sets [#4, #15, #19, #30]. Beyond activation, PU.1 enforces lineage repression: it recruits HDAC1 to deacetylate bound enhancers (reinforced by PRC2-deposited H3K27me3) to silence erythroid and innate-immune programs, and partners with pRB to block GATA-1-driven erythroid differentiation [#7, #25, #29]. PU.1 transactivates cytokine-receptor genes including c-fms and IL-7Rα to license lineage-specific cytokine responsiveness, and it is itself controlled by a regulatory architecture spanning TNF-induced induction in HSCs, GATA-1/GATA-2 repression of its locus, Runx1 action at its upstream regulatory element, and cell-cycle-coupled positive autoregulation [#2, #6, #12, #14, #24, #42]. PU.1 acts as a hematopoietic euchromatin gatekeeper whose haploinsufficiency causes agammaglobulinemia in humans, and hypomorphic PU.1 cooperates with mismatch-repair or Tet2 deficiency to drive AML, a context in which minor-groove-binding diamidines that allosterically disrupt PU.1-chromatin contacts show therapeutic activity [#21, #28, #43]. PU.1 additionally drives pro-fibrotic fibroblast programs, and its pharmacological inactivation reverses fibrosis [#23].\"\n,\n  \"teleology\": [\n    {\n      \"year\": 1988,\n      \"claim\": \"Established the locus as a candidate oncogene by linking its activation to virally induced leukemia, motivating all subsequent functional study.\",\n      \"evidence\": \"Retroviral integration site and expression analysis across murine erythroleukemia tumors\",\n      \"pmids\": [\"2827041\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the protein's molecular activity\", \"No mechanism linking overexpression to transformation\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Resolved whether PU.1 is required for hematopoietic development by showing its DNA-binding function is essential for B cell and macrophage differentiation while sparing erythroid/megakaryocytic lineages.\",\n      \"evidence\": \"Targeted disruption of the PU.1 DNA-binding domain in mice with histology and flow cytometry\",\n      \"pmids\": [\"8896458\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct target genes not identified\", \"Did not separate lineage-specification from terminal-differentiation roles\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Defined how PU.1 enables lineage-specific cytokine responsiveness by showing it is required for transcription of the M-CSF receptor c-fms, and separated receptor expression from differentiation.\",\n      \"evidence\": \"PU.1-null progenitors with retroviral c-fms rescue and cytokine assays; parallel functional analysis of null neutrophils\",\n      \"pmids\": [\"9687512\", \"9716585\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor rescue did not restore differentiation, leaving differentiation targets undefined\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Provided biochemical/structural basis for combinatorial control by demonstrating spacing-dependent cooperative DNA binding between PU.1 and IRF-4 through their DNA-binding domains.\",\n      \"evidence\": \"Fluorescence polarization, NMR, and domain-deletion analysis at the lambdaB element; in vivo Co-IP with TLS/FUS as an additional interactor\",\n      \"pmids\": [\"9642085\", \"9478924\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic structure of the cooperative complex not yet resolved\", \"TLS/FUS interaction was Medium-confidence single-lab\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Delivered the atomic basis for PU.1/IRF cooperativity, explaining how composite elements select cooperative versus anticooperative pairings, and extended PU.1's reach into lymphoid cytokine signaling via IL-7Rα.\",\n      \"evidence\": \"X-ray structure of PU.1/IRF-4/DNA ternary complex; promoter analysis and retroviral IL-7Rα rescue in null progenitors\",\n      \"pmids\": [\"12453417\", \"11869689\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure used isolated DNA-binding domains, not full-length factors\", \"Did not address nucleosomal context\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Showed PU.1 acts as a repressor of competing lineages by binding GATA-1 and recruiting pRB to block erythroid differentiation, establishing antagonistic cross-regulation of fate.\",\n      \"evidence\": \"Co-IP, domain mutagenesis, ChIP, and differentiation assays in MEL cells\",\n      \"pmids\": [\"14559995\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide scope of PU.1-pRB co-occupancy not defined\", \"In vivo relevance not tested\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identified post-translational and dose-based tuning of PU.1 output: p300 acetylation of specific lysines modulates transactivation, and PU.1 down-regulation marks the earliest molecular step restricting CMPs to erythroid/megakaryocytic fate.\",\n      \"evidence\": \"In vitro acetylation, mutagenesis, ChIP and reporter assays; PU.1-GFP reporter knock-in mice with in vivo reconstitution\",\n      \"pmids\": [\"16210620\", \"15657291\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Acetyltransferase/deacetylase balance in vivo not mapped\", \"Upstream signals setting PU.1 dose not yet identified\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Demonstrated PU.1's instructive sufficiency by showing PU.1 (with C/EBP) transdifferentiates fibroblasts into functional macrophage-like cells.\",\n      \"evidence\": \"Retroviral transcription-factor transduction into fibroblasts with phagocytosis and marker assays\",\n      \"pmids\": [\"18424555\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the chromatin mechanism enabling conversion\", \"C/EBP dependency not mechanistically dissected\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Expanded PU.1's regulatory repertoire to non-coding RNA, showing it directly drives myeloid-instructive microRNAs in vivo.\",\n      \"evidence\": \"ChIP-seq, retroviral HSC overexpression with transplantation, zebrafish morpholino knockdown\",\n      \"pmids\": [\"21730352\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of miRNA versus protein-coding targets to fate unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Explained how PU.1 dose is stabilized during commitment by uncovering a cell-cycle-coupled positive autoregulatory circuit.\",\n      \"evidence\": \"Quantitative live-cell imaging of a PU.1 reporter with mathematical modeling\",\n      \"pmids\": [\"23868921\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular link between cell-cycle length and PU.1 accumulation not defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Mapped PU.1 locus regulation and B-lineage programming, defining CTCF/SMARCA5 recruitment to the SPI1 enhancer and the reciprocal IRF8 versus IRF4 partnerships controlling B-cell differentiation.\",\n      \"evidence\": \"Conditional B-cell knockout with expression analysis; ChIP and demethylation experiments at the SPI1 locus\",\n      \"pmids\": [\"25288399\", \"24498324\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CTCF/SMARCA5 result was Medium-confidence single-lab\", \"Direct DNA contacts of IRF8-PU.1 at B-cell targets not structurally resolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Causally linked PU.1 dose reduction to leukemogenesis, showing hypomorphic PU.1 plus MMR deficiency generates preleukemic stem cells and AML through Irf8 inhibition.\",\n      \"evidence\": \"PU.1 enhancer-deletion mouse crossed to MMR-deficient mice with transplantation and expression profiling\",\n      \"pmids\": [\"26343801\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the full PU.1-dependent network lost during transformation\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Provided a pharmacological strategy and senescence mechanism: minor-groove diamidines allosterically block PU.1-chromatin binding with AML activity, while PU.1 overexpression triggers DNA-binding-dependent senescence.\",\n      \"evidence\": \"Small-molecule inhibitors with ChIP and xenotransplant models; overexpression with domain mutants and senescence assays in vivo\",\n      \"pmids\": [\"29083320\", \"28912174\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Senescence study was Medium-confidence single-lab\", \"Selectivity of diamidines for PU.1 sites genome-wide not fully resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Resolved the diamidine mechanism and clarified PU.1's upstream control and partner switching: inhibitory diamidines act through DNA minor-groove binding (not protein binding), TNF is the principal PU.1-inducing signal in HSCs, and PU.1 swaps IRF8 for NFATc1 across osteoclast differentiation.\",\n      \"evidence\": \"FP and DNA-binding competition assays; in vivo TNF perturbation with single-cell imaging; ChIP-seq across BMM-to-osteoclast transition and microglial conditional deletion\",\n      \"pmids\": [\"27079976\", \"30301719\", \"30721543\", \"30484118\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How TNF signaling is transduced to PU.1 protein stabilization not detailed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established PU.1 as a repressive chromatin organizer beyond hematopoiesis: it recruits HDAC1 to restrain neutrophil enhancers and drives pro-fibrotic fibroblast programs reversible by PU.1 inactivation; Runx1 and PU.1 enforce its own URE-dependent maintenance in erythroid cells.\",\n      \"evidence\": \"Conditional Spi1 deletion with ATAC-seq/ChIP-seq and Co-IP; conditional/pharmacological PU.1 inactivation across fibrosis models; URE-deletion mouse with ChIP and ATAC-seq\",\n      \"pmids\": [\"30911105\", \"30700907\", \"31431533\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism switching PU.1 between activator and repressor functions per locus unresolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Reframed PU.1 pioneering: rather than directly accessing nucleosomes, PU.1 uses its acidic activation domain to recruit SWI/SNF for de novo chromatin opening and partner redistribution.\",\n      \"evidence\": \"In vitro nucleosome-binding assays plus genome-wide ChIP-seq/ATAC-seq with domain deletions; pro-T-cell perturbations defining affinity/concentration trade-offs\",\n      \"pmids\": [\"31964861\", \"30171019\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of nucleosome engagement not yet shown\", \"Identity of recruited remodeler subunits incompletely defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed PU.1 functions as a human euchromatin gatekeeper and an inflammation-restraining repressor: agammaglobulinemia-causing mutations destabilize PU.1 and close euchromatin, and PU.1 represses cell-cycle/protein-synthesis genes during IL-1 stress in HSCs.\",\n      \"evidence\": \"Patient SPI1 mutations in human HSPCs with ATAC-seq and differentiation; conditional HSC knockout with IL-1 stimulation and ChIP-seq\",\n      \"pmids\": [\"33951726\", \"33857288\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How haploinsufficiency selectively closes specific euchromatin domains not fully mapped\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined the mechanistic basis of PU.1-mediated repression and methylation-sensitive leukemogenesis: PU.1 recruits HDAC1 and synergizes with PRC2 at erythroid enhancers, while Tet2 loss plus hypomorphic PU.1 drives AML via hypermethylated PU.1 sites and failed myeloid enhancer activation.\",\n      \"evidence\": \"ChIP-seq/ATAC-seq/RNA-seq with HDAC/PRC2 inhibition in MEL cells; compound Tet2-KO/URE-deletion mouse genetics with WGBS and transplantation\",\n      \"pmids\": [\"35871293\", \"35820129\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Locus-specific cues directing PU.1 to repressive versus activating complexes unresolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Delivered the structural mechanism of PU.1 pioneering on a native nucleosome, showing H2A-dependent DNA unwrapping cooperative with C/EBPα and H1 displacement, and rationalizing an AML mutation.\",\n      \"evidence\": \"Cryo-EM/crystal structures of PU.1-nucleosome complexes with in vitro binding assays and Q218H mutant analysis; also IL-9/PU.1 feedback loop in arthritis (Medium)\",\n      \"pmids\": [\"38267599\", \"39164066\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structures captured a single enhancer context\", \"In vivo coupling of unwrapping to SWI/SNF recruitment not directly visualized\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved what locus-specific molecular determinants direct PU.1 between activating (SWI/SNF) and repressive (HDAC1/PRC2) chromatin programs, and how PU.1 dose, post-translational modification, and partner availability are integrated to set these choices genome-wide.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No unified model linking PU.1 concentration to activator-versus-repressor outcome at individual loci\", \"Determinants of cofactor selection (p300 vs HDAC1 vs PRC2) per site unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 2, 6, 7, 19, 26, 30]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [4, 15, 32, 35, 28]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [32]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [26, 25, 29]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [28]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [32, 26]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 2, 6, 26]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [25, 26, 29, 32]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [0, 9, 11, 14]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [3, 19, 25, 30, 39]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [1, 20, 28, 43]}\n    ],\n    \"complexes\": [\n      \"PU.1/IRF composite-element complex (with IRF4/IRF8)\",\n      \"PU.1/MITF osteoclast complex\"\n    ],\n    \"partners\": [\n      \"IRF4\",\n      \"IRF8\",\n      \"GATA1\",\n      \"RB1\",\n      \"MITF\",\n      \"HDAC1\",\n      \"CEBPA\",\n      \"NFATC1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}